

## List of Abbreviations

---

<b>AAFP</b>	American Academy of Family Physicians	<b>FCTC</b>	Framework Convention for Tobacco Control
<b>Add Health</b>	National Longitudinal Study of Adolescent Health	<b>FDA</b>	U.S. Food and Drug Administration
<b>ADHD</b>	attention deficit hyperactivity disorder	<b>FEF</b>	forced expiratory flow
<b>AFRO</b>	WHO Africa	<b>FEF<sub>25-75</sub></b>	FEF between 25% and 75% of forced vital capacity
<b>AHA</b>	American Heart Association	<b>FEV<sub>1</sub></b>	forced expiratory volume in 1 second
<b>ALA</b>	American Lung Association	<b>FLAVOR</b>	Fun Learning about Vitality, Origin, and Respect
<b>AMA</b>	American Medical Association	<b>FOK</b>	Focus on Kids
<b>ASSIST</b>	American Stop Smoking Intervention Study	<b>FTC</b>	Federal Trade Commission
<b>B&amp;W</b>	Brown & Williamson Tobacco Corporation	<b>FTND</b>	Fagerström Test of Nicotine Dependence
<b>BAT</b>	British American Tobacco	<b>FTQ</b>	Fagerström Tolerance Questionnaire
<b>BHR</b>	bronchial hyperresponsiveness	<b>FVC</b>	forced vital capacity
<b>BMI</b>	body mass index	<b>g</b>	gram
<b>BRFSS</b>	Behavioral Risk Factor Surveillance System	<b>GABA</b>	gamma-aminobutyric acid
<b>CAI</b>	computer-assisted interviewing	<b>GNAT</b>	Go/No-go Association Test
<b>CARDIA</b>	Coronary Artery Risk Development in Young Adults	<b>GRP</b>	gross rating point
<b>CDC</b>	Centers for Disease Control and Prevention	<b>GTSS</b>	Global Tobacco Surveillance System
<b>CEO</b>	chief executive officer	<b>GYTS</b>	Global Youth Tobacco Survey
<b>CHIPS</b>	Choosing Healthy Influences for a Positive Self	<b>HDL</b>	high-density lipoprotein
<b>CI</b>	confidence interval	<b>HONC</b>	Hooked on Nicotine Checklist
<b>COMMIT</b>	Community Intervention Trial for Smoking Cessation	<b>HSI</b>	Heaviness of Smoking Index
<b>COPD</b>	chronic obstructive pulmonary disease	<b>IARC</b>	International Agency for Research on Cancer
<b>CSAP</b>	Center for Substance Abuse Prevention	<b>IAT</b>	Implicit Association Test
<b>CT</b>	computed tomography	<b>ICC</b>	intraclass correlation coefficient
<b>D.A.R.E.</b>	Drug Abuse Resistance Education	<b>ICV</b>	Internet cigarette vendors
<b>DSM-IV</b>	<i>Diagnostic and Statistical Manual of Mental Disorders- 4th edition</i>	<b>IMBC</b>	Integrated Model of Behavior Change
<b>DVD</b>	digital video disc	<b>ImPACT</b>	Informed Parents and Kids Together
<b>DZ</b>	dizygotic	<b>IMPACT</b>	Initiatives to Mobilize for the Prevention and Control of Tobacco Use
<b>EDI</b>	Eating Disorders Inventory	<b>IOM</b>	Institute of Medicine
<b>ED-NOS</b>	eating disorders-not otherwise specified	<b>IRR</b>	incidence rate ratio
<b>EMRO</b>	WHO Eastern Mediterranean	<b>ISAAC</b>	International Study of Asthma and Allergies in Childhood
<b>ES</b>	effect size	<b>ISFP</b>	Iowa Strengthening Families Program
<b>ESFA</b>	European Smoking Prevention Framework Approach	<b>ITT</b>	intent to treat
<b>ESPAD</b>	European School Survey Project on Alcohol and Other Drugs	<b>kg</b>	kilogram
<b>EURO</b>	WHO Europe	<b>L</b>	liter
<b>FCC</b>	Federal Communications Commission	<b>LCA</b>	latent class analysis
<b>FCP</b>	Full Court Press	<b>LDL</b>	low-density lipoprotein
		<b>Legacy</b>	American Legacy Foundation
		<b>LST</b>	LifeSkills Training
		<b>LTA</b>	latent transition analysis

<b>MDD</b>	major depressive disorder	<b>RI</b>	relative improvement
<b>mFTQ</b>	modified Fagerström Tolerance Questionnaire	<b>RICO</b>	<i>Racketeer Influenced and Corrupt Organizations Act</i>
<b>mg</b>	milligram	<b>RJR</b>	R.J. Reynolds Tobacco Company
<b>MI</b>	myocardial infarction	<b>RR</b>	relative risk
<b>mL</b>	milliliter	<b>SAMHSA</b>	Substance Abuse and Mental Health Services Administration
<b>mm</b>	millimeter	<b>SCQ</b>	Smoking Consequences Questionnaire
<b>MPAA</b>	Motion Picture Association of America	<b>SCQ-S</b>	Smoking Consequences Questionnaire-Spanish
<b>MPP</b>	Midwestern Prevention Project	<b>SD</b>	standard deviation
<b>MRI</b>	magnetic resonance imaging	<b>SEARO</b>	WHO South-East Asia
<b>MSA</b>	metropolitan statistical area	<b>SES</b>	socioeconomic status
<b>MSS</b>	Minnesota Student Survey	<b>SEU</b>	subjective expected utility
<b>MTF</b>	Monitoring the Future	<b>SHOUT</b>	Students Helping Others Understand Tobacco
<b>MVPA</b>	moderate-to-vigorous intensity physical activity	<b>SIDS</b>	sudden infant death syndrome
<b>MZ</b>	monozygotic	<b>SMART</b>	Self-Management and Resistance Training
<b>NAAG</b>	National Association of Attorneys General	<b>SNP</b>	single nucleotide polymorphisms
<b>nAChR</b>	nicotinic acetylcholine receptor	<b>SOS</b>	Solutions for Smoking
<b>NARE</b>	negative affect relief expectancy	<b>SPM</b>	subsequent participating manufacturer
<b>NASBE</b>	National Association of State Boards of Education	<b>SSQ</b>	Smoking Situations Questionnaire
<b>NCI</b>	National Cancer Institute	<b>SYMATU</b>	Statewide Youth Movement Against Tobacco Use
<b>NDSS</b>	Nicotine Dependence Syndrome Scale	<b>TAPP</b>	Tobacco and Alcohol Prevention Project
<b>NELS</b>	National Education Longitudinal Study	<b>TCP</b>	tobacco prevention and control program
<b>NHANES</b>	National Health and Nutrition Examination Survey	<b>TNT</b>	Project Towards No Tobacco Use
<b>NHIS</b>	National Health Interview Survey	<b>TPB</b>	Theory of Planned Behavior
<b>NIH</b>	National Institutes of Health	<b>TPSAC</b>	Tobacco Product Scientific Advisory Committee
<b>NLSY97</b>	National Longitudinal Survey of Youth 1997 Cohort	<b>TRA</b>	Theory of Reasoned Action
<b>NPM</b>	nonparticipating manufacturer	<b>TRP</b>	total rating point
<b>NSDUH</b>	National Survey on Drug Use and Health	<b>TTI</b>	Theory of Triadic Influence
<b>NYTCP</b>	New York Tobacco Control Program	<b>TUTD</b>	Thumbs Up! Thumbs Down! Project
<b>NYTS</b>	National Youth Tobacco Survey	<b>UCSF</b>	University of California, San Francisco
<b>OECD</b>	Organisation for Economic Co-operation and Development	<b>UNC</b>	University of North Carolina
<b>OPM</b>	original participating manufacturer	<b>URI-TW</b>	upper respiratory infection-triggered wheezing
<b>OR</b>	odds ratio	<b>USDA</b>	U.S. Department of Agriculture
<b>OSH</b>	Office on Smoking and Health	<b>USDHHS</b>	U.S. Department of Health and Human Services
<b>PAHO</b>	WHO Pan American Health Organization	<b>USDHEW</b>	U.S. Department of Health, Education, and Welfare
<b>PDAY</b>	Pathobiological Determinants of Atherosclerosis in Youth	<b>USPS</b>	United States Postal Service
<b>PEF</b>	peak expiratory flow	<b>USPSTF</b>	U.S. Preventive Services Task Force
<b>PFDY</b>	Preparing for the Drug Free Years	<b>LDL</b>	very-low-density lipoprotein
<b>PSU</b>	primary sampling unit	<b>VTA</b>	ventral tegmental area
<b>PUP</b>	possession, use, and purchase	<b>WCSS</b>	Weight Control Smoking Scale
<b>QALY</b>	quality-adjusted life year	<b>WHO</b>	World Health Organization
<b>RCT</b>	randomized controlled trial	<b>WPRO</b>	WHO Western Pacific
		<b>YRBS</b>	Youth Risk Behavior Survey
		<b>YRBSS</b>	Youth Risk Behavior Surveillance System

# List of Tables and Figures

## Chapter 1

### Introduction, Summary, and Conclusions

Table 1.1 Four-level hierarchy for classifying the strength of causal inferences from available evidence 8

## Chapter 2

### The Health Consequences of Tobacco Use Among Young People

Table 2.1a Conclusions from previous Surgeon General's reports on the adverse effects of tobacco use and exposure to secondhand smoke in children and young adults 16

Table 2.1.b Level of certainty of causality reported in the 2004 and 2006 Surgeon General's reports 20

Table 2.2 Studies assessing belief that smoking controls body weight 33

Table 2.3 Studies assessing use of smoking to control body weight (school and population surveys) 46

Table 2.4 Studies assessing use of smoking to control body weight (clinical samples) 61

Table 2.5 Studies assessing association between smoking and body weight 71

Table 2.6 Studies assessing change in weight following smoking cessation 76

Table 2.7 Studies assessing change in weight following smoking initiation 78

Table 2.8 Longitudinal studies on the association between smoking and maximum attained level of forced expiratory volume in one second (FEV<sub>1</sub>), rates of growth, age of plateau in lung function, and age of onset of decline in lung function 81

Table 2.9 Cross-sectional studies on the association of smoking with childhood cough, bronchitis symptoms, shortness of breath, wheeze, and asthma 89

Table 2.10 Longitudinal studies on the association of smoking with cough, bronchitis symptoms, shortness of breath, wheeze, and asthma in cohorts followed since childhood 92

Table 2.11 Relationship between tobacco use and atherosclerosis or subclinical atherosclerosis 98

Table 2.12 Endothelial dysfunction in young smokers 103

Figure 2.1 Average age when a whole cigarette was smoked for the first time among 9th- to 12th- grade youth; Youth Risk Behavior Survey (YRBS) 1991–2009; United States 22

Figure 2.2 Body mass index (BMI) differences among smokers and nonsmokers by age group 75

Figure 2.3 Gender-specific effects of smoking on level of pulmonary function in youth 10–18 years of age 84

Figure 2.4 Mean rates of pulmonary function growth by age, gender, and category of smoking 85

Figure 2.5 Relationship of age and the number of cardiovascular risk factors with severity of atherosclerosis in the right coronary artery in males in the Pathobiological Determinants of Atherosclerosis in Youth study 100

## Chapter 3

### The Epidemiology of Tobacco Use Among Young People in the United States and Worldwide

Table 3.1 Sources of national data on tobacco use among young people; United States and worldwide 132

Table 3.2 Cumulative percentages of recalled age at which a respondent first used a cigarette and began smoking daily, by smoking status among 30- to 39-year-olds; National Survey on Drug Use and Health (NSDUH) 2010; United States 136

Table 3.3a Percentage of high school students and middle school students who currently smoke cigarettes, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 137

Table 3.3b Percentage of young adults (18–25 years old) who currently smoke cigarettes, by gender and race/ethnicity; National Survey on Drug Use and Health NDSUH (2010); United States 138

Table 3.4a	Percentage of high school students and middle school students who currently use smokeless tobacco, by gender and race/ethnicity and age/grade; Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 144	Figure 3.6	Trends in prevalence of current smokeless tobacco use over time among high school students (National Youth Risk Behavior Survey [YRBS]) and high school seniors (Monitoring the Future [MTF]), by gender and race/ethnicity; YRBS 1995–2009 and MTF 1987 (or 1993)–2010; United States 147
Table 3.4b	Percentage of young adults (18–25 years old) who currently use smokeless tobacco, by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2010; United States 146	Figure 3.7	Trends in the initiation of smokeless tobacco use over time among young adults (18- to 25-year olds), by gender and by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006 and 2010; United States 148
Table 3.5a	Percentage of high school students and middle school students who currently smoke cigars, by gender and race/ethnicity and age/grade; Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 145	Figure 3.8	Trends in the prevalence of current cigar smoking over time among high school students, by gender and by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1997–2009; United States 150
Table 3.5b	Percentage of young adults (18–25 years old) who currently smoke cigars, by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2010; United States 146	Figure 3.9	Trends in the initiation of cigar smoking over time among young adults (18- to 25-year-olds), by gender and by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006 and 2010; United States 151
Figure 3.1	Percentage of recalled age at which adult smokers first tried a cigarette and began smoking daily, among 30- to 39-year-old adult smokers, by smoking status; National Survey on Drug Use and Health (NSDUH) 2010; United States 135	Figure 3.10	Percentage of current cigarette smoking among adolescents (12- to 17-year-olds) and young adults (18- to 25-year-olds), by race/ethnicity and by gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 152
Figure 3.2	Percentage of middle school 8th graders, high school seniors, young adults (18–25 years of age), and adults ( $\geq 26$ years of age) who currently smoke cigarettes; National Youth Tobacco Survey (NYTS) 2009, and National Survey on Drug Use and Health (NSDUH) 2010; United States 139	Figure 3.11	Percentage of current cigarette smoking among 8th, 10th, and 12th graders, by parental education (as a proxy for socioeconomic status) and grade level; Monitoring the Future (MTS) 2002–2007; United States 153
Figure 3.3	Trends in the prevalence of current cigarette smoking over time among high school students, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 140	Figure 3.12	Percentage of current cigarette smoking among young adults (18- to 25-year-olds), by education and employment (as proxies for socioeconomic status); National Survey on Drug Use and Health (NSDUH) 2010; United States 154
Figure 3.4	Current high school cigarette smoking and projected rates if decline had continued; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 141	Figure 3.13	Prevalence of current use of multiple tobacco products among high school males who use tobacco; National Youth Risk Behavior Survey (YRBS) 2009; United States 155
Figure 3.5	Trends in the initiation of cigarette smoking over time among young adults (18- to 25-year-olds), by gender and race/ethnicity and age/grade; National Survey on Drug Use and Health (NSDUH) 2006 and 2010; United States 143	Figure 3.14	Percentage of youth 13–15 years of age who currently use any tobacco product, by gender; Global Youth Tobacco Survey (GYTS) 1999–2009; Brazil (Rio de Janeiro), China (Macao), India, Russian Federation, South Africa, and the Syrian Arab Republic 156

- Figure 3.15 Percentage of 13- to 15-year-olds who currently smoke cigarettes, by gender; Global Youth Tobacco Survey (GYTS) 1999–2007; worldwide 158
- Figure 3.16 Body mass index (BMI) by smoking status/frequency among high school seniors, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 2003–2009; United States 160
- Figure 3.17 Percentage of current cigarette smoking and smokeless tobacco use among 8th, 10th, and 12th graders, by grade level and academic performance; Monitoring the Future (MTF) 2002–2007; United States 162
- Figure 3.18 Percentage distribution of cigarette brands that adolescents (12- to 17-year-olds) and young adults (18- to 25-year-olds) who were current smokers preferred; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 163

**Chapter 3 Appendices**  
**The Epidemiology of Tobacco Use Among Young People in the United States and Worldwide**

- Table 3.1.1 Percentage of young people who have ever smoked cigarettes, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 227
- Table 3.1.2 Percentage of young people who currently smoke cigarettes, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 229
- Table 3.1.3 Percentage of current cigarette use among 12- to 17-year-olds, by race/ethnicity and gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 231
- Table 3.1.4 Percentage of current cigarette use among 18- to 25-year-olds, by race/ethnicity and gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 232
- Table 3.1.5 Percentage of current cigarette smoking, by various sociodemographic risk factors among 8th, 10th, and 12th graders; Monitoring the Future (MTF) 2002–2007; United States 233

- Table 3.1.6 Percentage of frequent cigarette smoking, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 234
- Table 3.1.7 Percentage of heavy cigarette smoking, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, and National Youth Tobacco Survey (NYTS) 2009; United States 236
- Table 3.1.8 Percentage distribution of smoking intensity among 9th–12th graders, by the number of cigarettes smoked per day during the 30 days preceding the survey; National Youth Risk Behavior Survey (YRBS) 2009; United States 237
- Table 3.1.9 Cumulative percentages of recalled age at which a respondent first used a cigarette and began smoking daily, by smoking status among 30- to 39-year-olds; National Survey on Drug Use and Health (NSDUH) 2010; United States 238
- Table 3.1.10 Percentage distribution of cigarette brands that 12- to 17-year-olds who were current smokers preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 239
- Table 3.1.11 Percentage distribution of cigarette brands that young adults 18–25 years of age who were current smokers preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 241
- Table 3.1.12 Percentage of 12- to 17-year-olds who had never smoked but were susceptible to starting to smoke cigarettes, by race/ethnicity and gender; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 243
- Table 3.1.13 Age or grade when respondents first used a cigarette, among those aged 17–18 years who had completed 11th grade, National Survey on Drug Use and Health (NSDUH) 2010; and among 12th graders, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 244

<p>Table 3.1.14 Age or grade when respondents first began smoking daily, among 17- to 18-year-olds who had completed 11th grade, National Survey on Drug Use and Health (NSDUH) 2010; and among 12th graders, Monitoring the Future (MTF) 2010; United States 244</p> <p>Table 3.1.15 Distribution of developmental trajectories of cigarette smoking across adolescence and young adulthood, 11–26 years of age, by gender and race/ethnicity; National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States 245</p> <p>Table 3.1.16 Distribution of developmental trajectories of cigarette smoking across adolescence and young adulthood, 11–26 years of age, by level of nicotine dependence (Fagerström scale); National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States 245</p> <p>Table 3.1.17 Percentage of young people (12–14 years of age at Wave I and 19–21 years of age at Wave III) who were characterized as never smokers, current smokers, or former smokers, by gender and race/ethnicity; National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States 246</p> <p>Table 3.1.18 Probability of transitioning from one stage of cigarette smoking to another, from Wave I (12–14 years of age) to Wave III (19–21 years of age); National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States 246</p> <p>Table 3.1.19 Percentage of young people (15–18 years of age at Wave I and 22–25 years of age at Wave III) who were characterized as never smokers, former smokers, nondaily smokers, or daily smokers, by gender and race/ethnicity; National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States 247</p> <p>Table 3.1.20 Probability of transitioning from one stage of cigarette smoking to another, from Wave I (15–18 years of age) to Wave III (22–25 years of age); National Longitudinal Study of Adolescent Health (Add Health) 1994–2002; United States 248</p> <p>Table 3.1.21 Predicted likelihood (%) of smoking in young adulthood (5 years later), by intensity of smoking among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States 249</p>	<p>Table 3.1.22 Intensity of smoking (%) in young adulthood (5–6 years later), by intensity of smoking among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States 249</p> <p>Table 3.1.23 Percentage change in the direction of intensity of smoking between senior year of high school and young adulthood (5–6 years later), among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States 250</p> <p>Table 3.1.24 Intensity of smoking in young adulthood (5–6 years later), by intensity of smoking in senior year of high school and expectation to smoke within 5 years, among 1996–2001 high school seniors; Monitoring the Future (MTF) 1996–2007; United States 251</p> <p>Table 3.1.25 Indicators of cigarette smoking and nicotine dependence among 12- to 17-year-olds smoking cigarettes during the previous 30 days; National Survey on Drug Use and Health (NSDUH) 2007–2010; United States 252</p> <p>Table 3.1.26 Indicators of cigarette smoking and nicotine dependence among 18- to 25-year-olds smoking cigarettes during the previous 30 days; National Survey on Drug Use and Health (NSDUH) 2007–2010; United States 254</p> <p>Table 3.1.27 Indicators of cigarette use and nicotine dependence among adults 26 years of age or older smoking cigarettes during the previous 30 days; National Survey on Drug Use and Health (NSDUH) 2007–2010; United States 256</p> <p>Table 3.1.28 Percentage of high school seniors who were smokers during the previous month, by gender and race/ethnicity; Monitoring the Future (MTF) 1976–2007; United States 257</p> <p>Table 3.1.29 Percentage of 20- to 44-year-olds who identified themselves as current smokers, by age group, race/ethnicity, and gender; National Health Interview Surveys (NHIS) 1978–2009; United States 258</p> <p>Table 3.1.30 Trends in the initiation of cigarette smoking over time among 12- to 17-year-olds at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 261</p>
---	---

<p>Table 3.1.31 Trends in the initiation of cigarette smoking over time among 18- to 25-year-olds at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 261</p> <p>Table 3.1.32 Percentage of high school senior smokers who answered “yes” to questions about interest in quitting smoking and attempts to quit smoking, by frequency of smoking during the past 30 days; Monitoring the Future (MTF) 1990–2009; United States 262</p> <p>Table 3.1.33 Prevalence of cigarette smoking among users of smokeless tobacco and among users of drugs (e.g., alcohol, marijuana, cocaine, and inhalants) and prevalence of other drug use among cigarette smokers, among male high school seniors; Monitoring the Future (MTF) 2002–2007; United States 262</p> <p>Table 3.1.34 Prevalence of cigarette smoking among users of other drugs (e.g., alcohol, marijuana, cocaine, and inhalants) and prevalence of other drug use by cigarette smokers, among female high school seniors; Monitoring the Future (MTF) 2002–2007; United States 263</p> <p>Table 3.1.35 Percentage distribution of grade in which high school seniors first (if ever) used cigarettes or alcohol, or both; Monitoring the Future (MTF) 2002–2007; United States 263</p> <p>Table 3.1.36 Percentage distribution of grade in which high school seniors first (if ever) used cigarettes or marijuana, or both; Monitoring the Future (MTF) 2002–2007; United States 264</p> <p>Table 3.1.37 Percentage distribution of grade in which high school seniors first (if ever) used cigarettes or cocaine, or both; Monitoring the Future (MTF) 2002–2007; United States 264</p> <p>Table 3.1.38 Body mass index by smoking status/frequency among high school seniors, by gender and race/ethnicity; National Youth Risk Behavior Survey (YRBS) 2003–2009; United States 265</p> <p>Table 3.1.39 Percentage of 12- to 17-year-olds and 18- to 25-year-olds who have experienced a major depressive episode, by smoking status/frequency, gender, and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2009–2010; United States 266</p>	<p>Table 3.1.40 Percentage of young people who have ever used smokeless tobacco, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, and National Youth Tobacco Survey (NYTS) 2009; United States 267</p> <p>Table 3.1.41 Percentage of young people who currently use smokeless tobacco, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 269</p> <p>Table 3.1.42 Prevalence of 8th-, 10th-, and 12th-grade males who currently use smokeless tobacco, by various sociodemographic risk factors; Monitoring the Future (MTF) 2002–2007; United States 271</p> <p>Table 3.1.43 Age at which high school senior respondents first used smokeless tobacco or cigars; National Youth Tobacco Survey (NYTS) 2009; United States 272</p> <p>Table 3.1.44 Percentage distribution of smokeless tobacco brands that youth 12–17 years of age who were current users of smokeless tobacco preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 273</p> <p>Table 3.1.45 Share of the smokeless tobacco market in 2008, by type and brand; the Maxwell Report; United States 275</p> <p>Table 3.1.46 Prevalence of smokeless tobacco use among cigarette smokers and users of drugs and prevalence of cigarette smoking and drug use among users of smokeless tobacco in the past 30 days, among male high school seniors; Monitoring the Future (MTF) 2002–2007 and National Survey on Drug Use and Health (NSDUH) 2010; United States 276</p> <p>Table 3.1.47 Percentage distribution of smokeless tobacco brands that young adults 18–25 years of age who were current users of smokeless preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 277</p> <p>Table 3.1.48 Percentage of young people who have ever smoked cigars, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010 and National Youth Tobacco Survey (NYTS) 2009; United States 279</p>
---	---

<p>Table 3.1.49 Percentage of young people and young adults 18–25 years of age who currently smoke cigars by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 280</p>	<p>Table 3.1.58 Trends in the initiation of smokeless tobacco use over time among young adults 18–25 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 292</p>
<p>Table 3.1.50 Percentage distribution of cigar brands that youth 12–17 years of age who currently smoke cigars preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 282</p>	<p>Table 3.1.59 Trends in the initiation of cigar smoking over time among youth 12–17 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 293</p>
<p>Table 3.1.51 Share of cigar market in 2008, by brand; the Maxwell Report; United States 284</p>	<p>Table 3.1.60 Trends in the initiation of cigar smoking over time among young adults 18–25 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 293</p>
<p>Table 3.1.52 Percentage distribution of cigar brands that young adults, 18–25 years of age who currently smoke cigars preferred, by gender, race/ethnicity, age, and region; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 285</p>	<p>Table 3.1.61 Trends in the initiation of cigarettes, smokeless tobacco, and cigars over time among youth 12–17 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 294</p>
<p>Table 3.1.53 Prevalence of cigar use among users of other tobacco products and drugs and prevalence of other tobacco products and drug use among cigar users, among youth 12–17 years of age; National Survey on Drug Use and Health (NSDUH) 2010; United States 287</p>	<p>Table 3.1.62 Trends in the initiation of cigarettes, smokeless tobacco, or cigars over time among young adults 18–25 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 294</p>
<p>Table 3.1.54 Prevalence of the use of bidis and kreteks among youth in grades 6–12, by gender and race/ethnicity; National Youth Tobacco Survey (NYTS) 2009; United States 288</p>	<p>Table 3.1.63 Percentage of youth 13–15 years of age who have ever smoked cigarettes, who first tried smoking when younger than 10 years of age, and among never smokers who are susceptible to starting to smoke within the next year, by gender; Global Youth Tobacco Survey 1999–2009; worldwide 295</p>
<p>Table 3.1.55 Percentage of young people currently using both cigarettes and smokeless tobacco, by gender, race/ethnicity, age/grade, and region; National Survey on Drug Use and Health (NSDUH) 2010, Monitoring the Future (MTF) 2010, National Youth Risk Behavior Survey (YRBS) 2009, and National Youth Tobacco Survey (NYTS) 2009; United States 289</p>	<p>Table 3.1.64 Percentage of youth 13–15 years of age who have smoked cigarettes on 1 or more days during the past 30 days, and of those who have smoked cigarettes on 20 or more of the past 30 days, by gender; Global Youth Tobacco Survey 1999–2009; worldwide 306</p>
<p>Table 3.1.56 Percentage distribution of grade in which male high school seniors first (if ever) used smokeless tobacco and cigarettes; Monitoring the Future (MTF) 2002–2007; United States 291</p>	<p>Table 3.1.65 Percentage of youth 13–15 years of age who currently smoke and always have or feel like having a cigarette first thing in the morning, who want to stop smoking, and who have tried to stop smoking during the past year, by gender; Global Youth Tobacco Survey 1999–2009; worldwide 317</p>
<p>Table 3.1.57 Trends in the initiation of smokeless tobacco use over time among youth 12–17 years of age at risk for initiation—number (in thousands) and percentage of initiates—by gender and race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 291</p>	

- Table 3.1.66 Percentage of youth 13–15 years of age who have used any form of tobacco during the past 30 days and who have used any form of tobacco other than cigarettes during the past 30 days, by gender; Global Youth Tobacco Survey (GYTS) 1999–2009; worldwide 328
- Table 3.1.67 Percentage of youth 16 years of age who have smoked 40 or more cigarettes in their lifetime and who currently smoke cigarettes, overall and by gender; European School Survey Project on Alcohol and other Drugs (ESPAD) 2007; Europe 337
- Figure 3.1.1 Percentage who currently smoke cigarettes, by age group and state; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 339
- Figure 3.1.2 Percentage who currently smoke cigarettes, by age group, state, and gender; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 341
- Figure 3.1.3 Prevalence of current cigarette smoking among 12- to 17-year-olds and those 26 years of age or older, by state; National Survey on Drug Use and Health (NSDUH) 2008–2010; United States 344
- Figure 3.1.4 Distribution of developmental trajectories of cigarette smoking across adolescence and young adulthood, from 11 to 26 years of age, overall; National Longitudinal Study of Adolescent Health (Add Health) 1994–1996, 2001–2002; United States 344
- Figure 3.1.5 Trends in prevalence (%) of ever smoking among young people over time, by grade level and gender; Monitoring the Future (MTF) 1975–2010; United States 345
- Figure 3.1.6 Trends in prevalence (%) of ever smoking among young people, by grade level and race/ethnicity; Monitoring the Future (MTF) 1976–2010 and National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 347
- Figure 3.1.7 Trends in prevalence (%) of ever smoking and current smoking among 9th–12th grade students, by gender; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 349
- Figure 3.1.8 Trends in prevalence (%) of current smoking among young people over time, by grade level; Monitoring the Future (MTF) 1975–2010; United States 350
- Figure 3.1.9 Trends in prevalence (%) of current cigarette smoking among young people over time, by grade level and race/ethnicity; Monitoring the Future (MTF) 1976–2010 and National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 352
- Figure 3.1.10 Trends in the prevalence (%) of current smoking among 9th- to 12th-grade students, by state; Youth Risk Behavior Survey (YRBS) 1991–2009; United States 354
- Figure 3.1.11 Trends in prevalence (%) of cigarette smoking among Hispanics, Blacks, and Whites, by age group; National Health Interview Survey (NHIS) 1978–2009; United States 359
- Figure 3.1.12 Trends in prevalence (%) of cigarette smoking among persons 20 years of age or older, by age group and race/ethnicity; National Health Interview Survey (NHIS) 1978–2009; United States 362
- Figure 3.1.13 Past-month cigarette use among young adults (18–25 years of age), by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 363
- Figure 3.1.14 Past-month cigarette use among young adults (18–25 years of age), by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 364
- Figure 3.1.15 Past-month cigarette use among young adults (18–25 years of age), by poverty level; National Survey on Drug Use and Health (NSDUH) 2005–2010; United States 364
- Figure 3.1.16 Trends in the intensity of smoking among high school seniors; Monitoring the Future (MTF) 1976–2010; United States 365
- Figure 3.1.17 Trends in cigarette brand preference for the top five cigarette brands among 12- to 17-year-olds who are current smokers, by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 366
- Figure 3.1.18 Trends in cigarette brand preference for the top five cigarette brands among 18- to 25-year-olds who are current smokers, by gender; National Survey on Drug Use & Health (NSDUH) 2002–2010; United States 367
- Figure 3.1.19 Trends in the percentage of former smokers among ever regular smokers who are high school seniors, over time, by gender; Monitoring the Future (MTF) 1976–2010; United States 368

- Figure 3.1.20 Trends in the percentage of high school seniors who believe that smoking is a serious health risk and percentage of high school seniors who have ever smoked; Monitoring the Future (MTF) 1975–2010; United States 368
- Figure 3.1.21 Trends in the percentage of young people who believe smoking is a “dirty habit,” by grade level; Monitoring the Future (MTF) 1991–2010; United States 369
- Figure 3.1.22 Trends in the percentage of high school seniors who believe their close friends would disapprove of their smoking one or more packs of cigarettes per day; Monitoring the Future (MTF) 1979–2010; United States 369
- Figure 3.1.23 Trends in the percentage of high school seniors who prefer to date nonsmokers, over time, by gender; Monitoring the Future (MTF) 1981–2010; United States 370
- Figure 3.1.24 Trends in the percentage of high school seniors who prefer to date nonsmokers, over time, by race/ethnicity; Monitoring the Future (MTF) 1981–2010; United States 370
- Figure 3.1.25 Trends in the percentage of young people who do not mind being around people who smoke, by grade level; Monitoring the Future (MTF) 1991–2010; United States 371
- Figure 3.1.26 Grade in which high school seniors had first tried cigarettes, smokeless tobacco, alcohol, marijuana, and cocaine among respondents who had ever used these substances by 12th grade; Monitoring the Future (MTF) 2002–2007; United States 371
- Figure 3.1.27 Trends in health risk outcomes and behaviors among high school senior cigarette smokers and nonsmokers; National Youth Risk Behavior Survey (YRBS) 1991–2009; United States 372
- Figure 3.1.28 Percentage who currently use smokeless tobacco, by age group and state; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 382
- Figure 3.1.29 Percentage who currently use smokeless tobacco, by age group, state, and gender; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 384
- Figure 3.1.30 Past-month smokeless tobacco use among young adults (18–25 years of age), by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 387
- Figure 3.1.31 Past-month smokeless tobacco use among young adults (18–25 years of age), by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 387
- Figure 3.1.32 Past-month smokeless tobacco use among young adults (18–25 years of age), by poverty level; National Survey on Drug Use and Health (NSDUH) 2005–2010; United States 388
- Figure 3.1.33 Trends in prevalence (%) of current smokeless tobacco use among young people, by grade level; Monitoring the Future (MTF) 1986–2010 and National Youth Risk Behavior Survey (YRBS) 1995–2009; United States 389
- Figure 3.1.34 Trends in prevalence (%) of current smokeless tobacco use among males, by grade level and race/ethnicity; Monitoring the Future (MTF) 1987–2010; United States 391
- Figure 3.1.35 Trends in the percentage of young people who believe that smokeless tobacco is a serious health risk and in the percentage of high school seniors who have ever used smokeless tobacco; Monitoring the Future (MTF) 1986–2010; United States 392
- Figure 3.1.36 Percentage who currently smoke cigars, by age group and state; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 393
- Figure 3.1.37 Past-month cigar use among young adults (18–25 years of age), by gender; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 394
- Figure 3.1.38 Past-month cigar use among young adults (18–25 years of age), by race/ethnicity; National Survey on Drug Use and Health (NSDUH) 2002–2010; United States 395
- Figure 3.1.39 Past-month cigar use among young adults (18–25 years of age), by poverty level; National Survey on Drug Use and Health (NSDUH) 2005–2010; United States 395
- Figure 3.1.40 Percentage who currently smoke cigars, by age group, state, and gender; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 396
- Figure 3.1.41 Trends in prevalence (%) of cigar use among young people, by gender and by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1997–2009; United States 399

Figure 3.1.42 Trends in current use of bidis and kreteks among young people, by gender and by race/ethnicity; National Youth Tobacco Survey (NYTS) for 1999, 2000, 2002, 2004, 2006, and 2009; United States 400

Figure 3.1.43 Prevalence of current use of multiple tobacco products among all males of high school age and only those males of high school age who report using tobacco; National Survey on Drug Use and Health (NSDUH) 2010 and National Youth Risk Behavior Survey (YRBS) 2009; United States 404

Figure 3.1.44 Trends in prevalence (%) of current use of two or more different tobacco products among students reporting any tobacco use, by gender and by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1997–2009; United States 405

Figure 3.1.45 Percentage of 13- to 15-year-olds who have ever smoked cigarettes, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 407

Figure 3.1.46 Percentage of 13- to 15-year-olds who currently smoke cigarettes, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 409

Figure 3.1.47 Percentage of 13- to 15-year-olds who currently smoke and want to stop smoking, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 411

Figure 3.1.48 Percentage of 13- to 15-year-olds who currently use other forms of tobacco than cigarettes, by gender; Global Youth Tobacco Survey 1999–2007; worldwide 413

Table 3.2.1 Measures of tobacco use, by source, 2008 and 2009 questionnaires; United States and worldwide 415

#### **Chapter 4 Social, Environmental, Cognitive, and Genetic Influences on the Use of Tobacco Among Youth**

Table 4.1 Prevalence of smoking in previous month among adolescents aged 16–19 years who have not completed 12th grade, by enrollment status in school; National Survey on Drug Use and Health (NSDUH) 2006–2010; United States 436

#### **Chapter 5 The Tobacco Industry's Influences on the Use of Tobacco Among Youth**

Table 5.1 Cigarette company marketing activities reported to the Federal Trade Commission (FTC) 489

Table 5.2 Detailed expenditures for cigarette marketing, in thousands of dollars, 2002–2008 492

Table 5.3 Cigarette company marketing expenditures, by major category, in millions of dollars, 1963–2008 495

Table 5.4 Cigarette company marketing expenditures, percentage of total by major category, in millions of dollars, 1975–2008 497

Table 5.5 Cigarette company marketing expenditures, by major category, in millions of dollars, 1975–2008 499

Table 5.6 Detailed expenditures for smokeless tobacco marketing, in thousands of dollars, 2002–2008 501

Table 5.7 Smokeless tobacco company marketing expenditures, by major category, in millions of dollars, 1988–2008 504

Table 5.8 Smokeless tobacco company marketing expenditures, by major category, in millions of dollars, 1988–2008 505

Table 5.9 Smokeless tobacco company marketing expenditures, percentage of total by major category, in millions of dollars, 1988–2008 506

Table 5.10 Controlled-exposure studies examining televised messages in the tobacco industry's campaign to prevent youth smoking 559

Table 5.11 Naturalistic studies examining the effect of televised campaigns of the tobacco industry on preventing youth smoking 562

Table 5.12 Content analyses of movies in studies published since 2005 572

Table 5.13 Population-based studies assessing the relation between exposure to movie smoking and smoking among young people 576

Table 5.14 Population-based studies assessing the relation between parental restrictions on viewing R-rated movies and smoking among adolescents 594

Figure 5.1 Structure supporting the effect of marketing on youth smoking based on the Theory of Triadic Influence 510

Figure 5.2 Cigarette prices and cigarette sales, United States, 1970–2011 525

Figure 5.3 Cigarette prices and prevalence of youth smoking by grade in school, United States, 1991–2011 526

Figure 5.4 Camel crush package and filter flavor pellet 538

Figure 5.5 Graduation strategy designed to encourage new smokeless tobacco users to start with products with low free nicotine content and progress to others with higher levels of free nicotine 540

Figure 5.6 Tobacco industry paradigm shift 553

Figure 5.7 Actor engaging an actress with a cigarette 565

Figure 5.8 “SHOUT, Mr. Tracy!”: actor enjoying a cigarette 566

Figure 5.9 Proportion of movies containing tobacco brand appearances in the top 100 box office hits released each year, 1996–2008 567

Figure 5.10 (A) Occurrences of smoking in highest-grossing movies, 1990–2007, and (B) smoking among eighth graders, 1991–2007, in the United States 568

Figure 5.11 Comparison of the trend for proportion of 5-minute movie segments with tobacco (means for 15 of the top 30 box office hits from 1950 to 2005) and per capita cigarette consumption among adults, 1950–2005, in the United States 570

Figure 5.12 Summary and meta-analysis of studies on the association between exposure to movie smoking and smoking among adolescents and young adults 590

Figure 5.13 Shape of the crude dose-response relation between exposure to movie smoking and smoking onset for German and U.S. samples of adolescents 591

Figure 5.14 Summary of results for studies on the association between parental movie restrictions and smoking among early adolescents 596

**Chapter 6**  
**Efforts to Prevent and Reduce Tobacco Use**  
**Among Young People**

---

Table 6.1 Summaries of controlled field trials of community-based mass media programs, by review(s) 638

Table 6.2 Summary of longitudinal and cross-sectional population-based studies examining the effects on youth of mass media antismoking campaigns 647

Table 6.3 Controlled exposure and naturalistic exposure studies examining the relative effectiveness of different advertising messages for youth 669

Table 6.4 Budgeted state funding of tobacco control programs in fiscal year 2011 in relation to funding levels recommended by the Centers for Disease Control and Prevention (CDC) 695

Table 6.5 Federal cigarette excise taxes, selected dates, 1993–2009 698

Table 6.6 Federal tax rates on other tobacco products, selected dates, 1993–2009 698

Table 6.7 State cigarette excise taxes (dollars per pack) and sales tax rate applied to cigarettes 700

Table 6.8 Descriptions and effect sizes (expressed as relative improvements) of parenting and family interventions for preventing use of tobacco among adolescents 722

Table 6.9 Studies of the effectiveness of school-based interventions to reduce tobacco use 735

Table 6.10 Studies of the effectiveness of multicomponent interventions that include school-based programs to reduce tobacco use 777

Table 6.11 Studies on smoking cessation among youth 794

Table 6.12 Youth cessation treatment means, 2006 and 2007 analyses, stratified by duration of follow-up 799

Table 6.13 Youth cessation treatment means, 2006 and 2007 analyses, stratified by theory 799

Table 6.14 Youth cessation treatment means, 2006 and 2007 analyses, stratified by modality 799

Table 6.15 Youth cessation treatment means, 2006 and 2007 analyses, stratified by number of sessions 799

Table 6.16 Studies on smokeless tobacco cessation for youth 805

Figure 6.1 Approaches to smoking prevention overlaid on the Theory of Triadic Influence (TTI) 634

Figure 6.2 Cigarette prices and prevalence of smoking among youth, 1975–2011 701

Figure 6.3 Map of 100% smoke-free air laws, United States, July 1, 2011 708

Figure 6.4 Synar noncompliance rate by year: average of 50 states and the District of Columbia weighted by state population 711

Figure 6.5 Health warnings on cigarette packages in the United States 716

Figure 6.6 Pictorial warning on cigarette package in Canada 717

Figure 6.7 Pictorial warning on cigarette package in Australia 718

Figure 6.8 Proposed pictorial warnings on cigarette packages in the United States 719

**Chapter 7**  
**A Vision for Ending the Tobacco Epidemic**

---

Table 7.1 Cumulative percentages of recalled age at which respondents first tried a cigarette and began to smoke daily among 30- to 39-year-olds who have ever smoked daily, 1991 compared with 2010 851

Table 7.2 Strategic actions to end the tobacco epidemic 855

Figure 7.1 Current rates of cigarette smoking among high school students and projected rates if the 1997–2003 decline had continued; Youth Risk Behavior Survey (YRBS) 1991–2009; United States 856



# Index

---

## A

---

- AAP. *See* American Academy of Pediatrics
- abdominal aorta, atherosclerosis in, 100–101
- academic achievement, 161–162, 434–436
- current smoking prevalence by, 175, 233, 436
  - smokeless tobacco use by, 201, 271
- accessibility of tobacco
- industry-sponsored prevention programs, 555–557
  - physical environment, 437–438 (*See also* retail outlets)
  - regulations on, 710–712
- acculturation, 432–433
- “Action Against Access” program, 556–557
- activism, youth, 789–792
- ADAMHA. *See* *Alcohol, Drug Abuse, Mental Health Administration Reorganization Act*
- Add Health. *See* National Longitudinal Study of Adolescent Health
- addiction. *See* nicotine addiction
- additives, 536–537. *See also* flavor additives
- ADHD. *See* attention deficit hyperactivity disorder
- adolescent, definition of, 6
- Adolescent Dieting Scale, 64
- adult smokers. *See also* parental smoking; young adults
- antismoking campaigns targeting, 690
  - brand-specific advertising for, 517–518
- advertising, 508–522. *See also* marketing practices
- bans (*See* advertising bans)
  - definition of, 712–713
  - expenditures, 488–507
    - cigarettes, 488–500
    - smokeless tobacco, 491, 501–507  - imagery in, 508, 519
    - brand packaging, 530–533, 535
    - broadcast media (*See* movie smoking; television advertising)  - impact evaluation, validity of, 438, 514, 713–714
  - in retail stores (*See* point-of-sale marketing)
  - of smoking cessation products, 635
  - summary, 487, 508–509, 851–852
  - themes used in, 508, 519, 599
  - types of, 488–490
  - weight control emphasized in, 31, 530–532
- advertising bans, 712–715
- digital marketing, 547
  - econometric analyses of, 514
  - effectiveness of, 438, 598–599
    - current evidence base, 714–715
    - discussion, 715, 810–811
    - prior review, 714
    - statistical issues, 713–714  - mass media, 507, 566, 574, 635
  - Master Settlement Agreement (*See* Master Settlement Agreement)
  - point-of-sale, 534, 545
  - “1996 rule” (FDA), 491
  - sponsorships, 491, 534
- affective processes, 445–447, 450
- smoking prevention and, 632–633, 731
- Africa (AFRO), tobacco use, 209–210
- age of onset/ever smoked, 295–297, 407–408
  - current prevalence, 317–319, 328–330, 409–410
  - intensity of smoking, 306–308
  - smoking cessation, 317–319, 411–412
- African Americans
- epidemiology (*See* racial/ethnic groups)
  - menthol cigarette use, 432, 543
- AFRO. *See* Africa region
- age at onset. *See also* initiation of smoking
- epidemiology, 134–136, 164, 238, 244, 295–305
    - developmental patterns, 179–180, 245–248, 344
    - trends, 22, 190–191, 294, 851  - genetic factors, 453–454
  - health consequences related to, 22
  - nicotine addiction and, 184
  - smokeless tobacco use, 201, 272, 291–293
  - substance use comorbidity, 29, 193, 263–264, 371
- age-of-sale laws, 555–557, 710–712
- age-related processes. *See* developmental risk factors
- AHA. *See* American Heart Association
- air pollution. *See* clean air policies; secondhand smoke
- ALA. *See* American Lung Association
- Alaska Natives
- epidemiology (*See* racial/ethnic groups)
  - religious use of tobacco, 431–433
  - smokeless tobacco use, 803–804, 808
- Al Capone (brand), 282, 286
- Alcohol, Drug Abuse, Mental Health Administration (ADAMHA) Reorganization Act* (1992), 631, 710–712, 810, 854
- alcohol use
- nicotine addiction and, 184–185, 252–255
  - prevalence of, 194, 372
  - psychiatric comorbidity, 27–28
  - tobacco use comorbidity, 193–194, 203, 205–206, 263, 276, 287, 371
  - tobacco use risk, 28–29
- Altria Group, Inc., 488, 555. *See also* Philip Morris
- AMA. *See* American Medical Association
- American Academy of Pediatrics (AAP), 727–728

- American Heart Association (AHA) grading system, 97–100
- American Indians
- epidemiology (*See* racial/ethnic groups)
  - religious use of tobacco, 431–433
  - smokeless tobacco use, 803–804, 808
  - tax exemption, 706
- American Legacy Foundation
- creation of, 4, 850
  - Media Tracking Surveys, 688
  - social networking campaign, 688
  - tobacco industry payments to, 852
  - “truth” ads, 558, 561, 635, 687–690, 850
  - YE (Youth Empowerment) Work Group, 789
- American Lung Association (ALA), 553
- American Medical Association (AMA), 694, 727
- American Nonsmokers' Rights Foundation, 707
- American Psychiatric Association, 23–24
- American Smokers Alliance, 550
- American Snuff Company, 202, 539–540
- American Stop Smoking Intervention Study for Cancer Prevention (ASSIST), 694, 696, 786
- American Tobacco Company, 31, 487
- Americas (PAHO), tobacco use, 209–210
- age of onset/ever smoked, 297–300, 407–408
  - current prevalence, 319–322, 330–331, 409–410
  - intensity of smoking, 308–311
  - smoking cessation, 319–322, 411–412
- ammoniated products, 536–537
- Amsterdam Growth and Health Study (Netherlands), 83
- animal studies
- cardiovascular effects, 96–97
  - nicotine withdrawal, 456
- antioxidant levels, 95–96
- antitobacco policies
- antismoking campaigns (*See* smoking prevention)
  - government-level (*See* tobacco control policies)
  - home-based, 709–710
  - school-based, 435, 707–709, 787–788
- anxiety disorders, 27–28, 445–447
- aortic pulse wave velocity, 108
- apolipoprotein E (Apo E) knockout mice, 96
- appetite control, 43, 58–59, 63. *See also* weight control
- “area effect” of smoking, 434
- Argentina, weight control behavior, 58–59
- Ariva (brand), 533
- Arizona, tobacco control program, 694, 696
- Asian youth. *See* racial/ethnic groups
- ASPIRE program, 786
- ASSIST. *See* American Stop Smoking Intervention Study for Cancer Prevention
- associations, 449, 533
- asthma, 87–94
- definition of, 87
  - epidemiologic evidence
    - cross-sectional studies, 88–91
    - prospective cohort studies, 91–94
  - lung growth and, 86
  - summary, 94
- atherosclerosis
- postmortem studies, 97–101
  - subclinical, 101–102
  - summary, 101
  - vascular injury in, 96
- attention deficit hyperactivity disorder (ADHD), 27–28
- attitudes toward smoking
- affective processes, 445–447, 451
  - antitobacco industry, 554–555, 558, 561, 635
  - cognitive processes, 447–451, 459
  - epidemiology, 191–192, 369–371
  - family context, 443–445
  - large social environment, 431–437
  - marketing and, 509, 512, 519–522, 532–533, 544
  - movie smoking and, 596–598
  - peer groups, 439–443, 519–522
  - in schools, 788
  - smoking prevention and, 558, 561, 632–633, 686–690
  - trends in, 192, 431
- audience segmentation, in antismoking campaigns, 689–691
- audiovisual advertising, expenditures on, 489, 501–502
- Australia
- endothelial dysfunction study, 102
  - health warnings, 717–718
  - lung function studies, 86
  - marketing practices, 511, 513, 517, 531, 533, 535, 548
  - school tobacco policies, 788
  - smoking prevention programs, 558, 690, 692, 721
  - weight control behavior, 64
- automatic cognitive processes, 448–451
- awareness of smoking, 511–512
- 
- ## B
- Bacall, Lauren, 565
- Backwoods (brand), 283–284, 286
- Balanced Budget Act* (1997), 698
- Barker, David, 21
- Barker hypothesis, 21
- bars, promotional activities in, 522, 534
- Basic, 366–367
- BAT. *See* British American Tobacco
- B&W. *See* Brown & Williamson
- Beach method, 571, 574
- Beech-Nut, 274, 278
- behavioral risk factors
- health-related, 194–197, 372–381, 633
  - marketing influences, 509, 512–513, 599
  - mental health issues, 27–28
  - tobacco use, 427–429 (*See also* etiology of tobacco use; smoking behavior)
  - smoking prevention based on, 631–632, 636–637, 809
- Behavioral Risk Factor Surveillance System (BRFSS), 201, 697, 703
- “below the line” marketing activities, 534
- Bernays, Edward L., 565

- BE smokeFREE program, 721, 726  
*Best Practices for Comprehensive Tobacco Control Programs Guide* (CDC), 711, 809, 853  
 BHR. *See* bronchial hyperresponsiveness  
 bias, in advertising impact studies, 713–714  
 bidis  
   measures of use, 217, 423  
   prevalence of use, 206–207, 288, 400–401  
 billboard advertising  
   antismoking messages, 688  
   tobacco industry expenditures on  
     cigarettes, 489, 491–493  
     smokeless tobacco, 501–502  
 biological risk factors, 428  
 bipolar disorder, 27  
 birth weight, 96, 108  
 Black & Mild (brand), 164, 205, 282, 285, 539  
 blood pressure, 97, 199  
 blunts, 205–206, 287  
 BMI. *See* body mass index  
 body image, 44–45, 57, 64–65, 68  
 body mass index (BMI), 44, 70–75  
 body weight, 69–79  
   after initiation of smoking, 75–79  
   after smoking cessation, 59, 69, 75–77  
   control of (*See* weight control)  
   epidemiologic findings, 157–161, 196–198, 265, 377–378  
   low birth weight, 96, 108  
   of smokers, 69–75  
 Bogalusa Heart Study, 100–102, 108–109  
 Bogart, Humphrey, 565  
 bogus pipeline, 215  
 Bonsack, James, 487  
 bonus products, expenditures on, 490–492, 494, 502–503  
 book covers, smoking prevention campaign using, 554  
 Boys & Girls Clubs of America, 555, 692  
 brachial artery, vascular reactivity in, 102, 108  
 brain development, 428, 451, 455–459  
 brand(s). *See also* specific brand  
   descriptors, 31, 530–532, 697  
   development of (*See also* product design)  
     expenditures on, 488  
   discount, 523–526, 547  
   loyalty to, 516, 518–519  
   marketing specific to, 161–164, 177, 507, 516–522  
   packaging of, 530–531 (*See also* packaging)  
   recognition of, 511–512, 516  
 brand ambassadors, 546, 552  
 branded merchandise, expenditures on  
   cigarettes, 490–493, 497–500  
   smokeless tobacco, 501, 505–506  
 branded products, in movies, 566–567  
 brand preferences  
   changes in, 516–518  
   cigarettes, 161–164, 177–178, 190, 239–242, 366–367, 507, 536, 850  
   cigars, 164, 205, 282–286  
   definitions of, 216–217, 418, 421, 423  
   packaging and, 530–531  
   smokeless tobacco, 164, 201–202, 273–275, 277–278  
 Brazil, health warnings, 719  
 Breathe California-Sacramento Emigrant Trails, 569  
 breathlessness, 88–94  
 BRFSS. *See* Behavioral Risk Factor Surveillance System  
 British American Tobacco (BAT), 528, 534  
 broadcast advertising. *See* mass media advertising  
 bronchial hyperresponsiveness (BHR), 88, 94  
 bronchitis, 88–94  
 Brown & Williamson (B&W). *See also* Reynolds American, Inc.  
   digital marketing, 546  
   Kool brand (*See* Kool)  
   marketing expenditures, 488  
   product design, 537–538  
   smoking prevention program, 554–555  
 Brundtland, Gro Harlem, 857  
 built environment, 437–438  
 bulimia, 60–64  
 bupropion, 800  
 Busselton Health Study, 726
- ## C
- 
- CAI. *See* computer-assisted interviewing  
 California, tobacco control program, 694, 696, 853  
 Camel (brand)  
   ad campaigns, 515–516  
   brand-specific marketing, 516, 518–519, 521  
   Camel Crush, 537–538  
   Camel Snus, 274, 278, 507, 540, 549  
   dissolvables, 507, 540  
   flavor additives, 538–539  
   image advertising, 519  
   Joe Camel persona, 511–512, 516, 518–519, 521, 537, 849  
   market share, 161–164, 177–178, 190, 239–242, 366–367, 507, 850  
   price promotions, 491, 528–529  
   product design, 535–537  
   Web site, 546, 548  
   youth-directed advertising, 519  
 Canada  
   academic achievement studies, 161  
   health warnings, 716–717, 719  
   marketing practices, 531–534, 543–545  
   school-based programs, 788, 791  
   socioeconomic factors, 434  
   weight control behavior, 57  
 cancer  
   epidemiology, 188  
   smokeless tobacco-related, 199, 806, 808  
 candidate gene studies, 452  
 candy flavoring. *See* flavor additives  
 Capri (brand), 31  
 Captain Black (brand), 540  
 carbonates, 536

- carbowax, 537
- CARDIA. *See* Coronary Artery Risk Development in Young Adults
- cardiovascular consequences, 94–109
  - atherosclerosis, 97–102
  - endothelial dysfunction, 102–108
  - evidence review methods, 96
  - insulin resistance, 109
  - lipids, 108–109
  - physiological effects, 97
  - prenatal exposure, 94
  - smokeless tobacco use, 199
  - summary, 109
  - vascular injury, 95–96
- Cardiovascular Risk in Young Finns study, 101–102
- Carolina Population Center (UNC-Chapel Hill), 212
- carotid arteries, atherosclerosis in, 101–102
- Caufield, R.T., 521
- causal criteria, 7–8
- causation, levels of, 631–632. *See also* etiology of tobacco use
- CDC. *See* Centers for Disease Control and Prevention
- Center for Substance Abuse Prevention (CSAP), 720
- Centers for Disease Control and Prevention (CDC), 7
  - Behavioral Risk Factor Surveillance System (BRFSS), 201, 697, 703
  - Best Practices for Comprehensive Tobacco Control Programs Guide*, 711, 809, 853
  - Global Tobacco Surveillance System (GTSS), 156, 209–210
  - IMPACT program, 694, 696
  - Media Campaign Resource Center, 636
  - movie smoking analyses, 569, 598
  - National Center for Health Statistics, 212
  - National Tobacco Control Program, 694, 696
  - school-based program recommendations, 732
  - School Health Policies and Programs Study, 707
  - tobacco control funding recommendations, 695–696
- central processing systems, in communication theory, 636
- cessation
  - smokeless tobacco use, 804–808
  - smoking (*See* smoking cessation)
- Changing Adolescent Smoking Prevalence* (NCI Monograph 14), 5
- checkout counter, advertising positioned by, 543–544
- Chesterfield (brand), 31
- Chewer's Choice program, 807
- chewing tobacco. *See* smokeless tobacco
- Chilcote, Samuel D., Jr., 555
- children
  - awareness of smoking, 511–512
  - definition of, 6
  - weight control beliefs, 32–43
- Chile, respiratory disease, 88
- China
  - cultural influences on smoking, 433
  - endothelial dysfunction study, 102
- cholesterol, 108–109
- cholinergic nicotinic subunit receptor genes (*CHRNA5/A3/B4*), 26
- chronic obstructive pulmonary disease (COPD), 80, 86, 88
- cigars
  - definition of, 203
  - digital marketing of, 549
  - flavored, 155, 205
  - online sales of, 547
  - pricing, 155, 706
  - taxes on, 698
- cigar smoking
  - brand preferences, 164, 205, 282–286
  - current prevalence, 142, 145, 165, 203–205, 280–281, 374, 393–398
  - disparities, 154
  - etiology of, 430
  - ever used, 203, 279
  - genetic factors, 454
  - measures of, 217, 421–423
  - multiple tobacco product use, 154–155, 165, 205–209, 287, 289–290, 404
  - substance use comorbidity, 287
  - trend data, 149–151, 195, 205, 294, 399
- Citi Investment Research, 533
- clean air policies, 707–710
  - home-based, 709–710
  - impact on tobacco use, 708–709
  - school-based, 435, 707–709, 787–788
  - smokeless tobacco products and, 541, 549, 551
  - social norms created by, 437
  - state-level, 697
  - summary, 710, 810
- Clean Indoor Air Act* (2003), 697
- clinical interventions, 727–731
  - barriers to, 730–731
  - delivery rates, 728–729
  - guidelines, 727–728, 731
  - research support, 729–730
  - smokeless tobacco use, 802, 807
  - smoking cessation, 799–801
  - summary, 731
  - theories underlying, 633–634
- clinical studies, weight control behavior, 60–63
- clove cigars, 155, 205
- clove cigarettes (kreteks)
  - measures of use, 217, 423–424
  - prevalence of use, 206–207, 288, 402–403
- cocaine use
  - prevalence of, 195, 373
  - tobacco use comorbidity, 193–194, 203, 263–264, 276, 287, 371
  - tobacco use risk, 28–29
- Cochrane reviews, 5
  - marketing practices, 516–517
  - smoking prevention, 683, 692
    - cessation programs, 793
    - family interventions, 720–727
    - school-based programs, 732–734
    - youth access, 711–712, 810

cognitive processes, 447–451, 459  
 neurodevelopmental, 451, 456–459  
 smoking prevention and, 632–633

coherence of association, 7

Cohiba (brand), 283, 286

color of packaging, 530, 532–533

COMMIT. *See* Community Intervention Trial for Smoking Cessation

Commonwealth Brands, Inc., 488

communication theories, 636–637, 686

Communities that Care (CTC) program, 786

community interventions, 692–693  
 evaluation methods, 634  
 evidence summary, 811  
 industry-sponsored, 555  
 mass media (*See* mass media antismoking campaigns)  
 smokeless tobacco use, 802–803, 806  
 youth empowerment and activism, 789–792

Community Intervention Trial for Smoking Cessation (COMMIT), 693

Community Preventive Services Task Force, 5, 712, 810

computer-assisted interviewing (CAI), 131, 213

conclusions  
 major, 8  
 epidemiology, 9, 165  
 etiology of tobacco use, 10, 460  
 health consequences, 9, 111  
 from previous Surgeon General's Reports, 4, 15–21  
 tobacco industry practices, 10, 601–602  
 tobacco use prevention, 10, 812

condom use, 195, 375

conduct disorders, 27–28

consistency of association, 7

contemplation stage, 430

content analysis, movie smoking, 566, 571–574

controlled cognitive factors, 447–448, 450–451

controlled-exposure studies, 558–563, 637–646, 683–688

convenience stores, 543–544

Conwood Tobacco Company (American Snuff Company), 202, 539–540

COPD. *See* chronic obstructive pulmonary disease

Copenhagen (brand)  
 market share, 201–202, 273, 275, 277  
 packaging, 531  
 product design, 540  
 Web site, 548

coping theories, 447–448

copy-test studies, 686–687

coronary arteries, atherosclerosis in, 100–101

Coronary Artery Risk Development in Young Adults (CARDIA) study, 75, 83, 97, 101–102, 109

cotinine levels, 108, 710

cough, 88–94

counseling. *See* clinical interventions

counter displays, 543–544

coupons. *See* price promotions

credit card payments, for online tobacco sales, 548

cross-promotion arrangements, tobacco/movie industry, 565

“crush” concept, 537–538

CSAP. *See* Center for Substance Abuse Prevention

CTC. *See* Communities that Care

cultural-environmental stream, 509–511, 599, 632–634

cultural influences, 432–433, 509  
 family interventions, 726–727  
 school-based programs, 787

Current Population Surveys, 709  
 Tobacco Use Supplement to the, 177, 435, 705, 707–708

current smoking  
 definition of, 216, 415, 419–424  
 prevalence of (*See* epidemiology)

curriculum interventions, 802–803

## D

---

Daniels, Draper, 518

D.A.R.E. (Drug Abuse Resistance Education) program, 725, 732, 788–789

D.A.R.E. Plus (Play and Learn Under Supervision) program, 725, 727

data analysis, 134

data collection methods, 215–217, 713–714

data sources, 131–133, 210–214

deceptive advertising, brand descriptors as, 531–532

deep sequencing, 453

deliberate processing of information, 447–448

demand, price elasticity of, 699–706

depressive disorders, 27–28  
 affective processes, 445–447  
 epidemiology, 198, 266  
 suicidal ideation, 195–196, 376

descriptors, brand, 31, 530–532, 697

desire to smoke, influence of advertising on, 512, 532–533

developmental disorders, 27–28

developmental patterns of smoking, 429–430  
 epidemiology, 179–185, 245–248  
 genetic influences, 25–26, 456–457  
 marketing influences, 515–516

developmental risk factors, 428–429  
 neurobiological, 451, 455–459  
 smoking prevention based on, 632–633

DHL, 548

diabetes, 109

*Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)*, 23–24

diammonium phosphate, 536–537

diet, 196, 379–380

diETING  
 initiation of smoking and, 64–65, 68  
 smoking behavior and, 44–45, 57–60

Digianni, John, 530

digital marketing, 546–552  
 bans on, 547  
 cessation programs, 800–801, 807  
 cigars, 549

- expenditures on, 490, 493–494, 502–503, 546
- image advertising in, 438
- increased use of, 508
- key features of, 546
- online tobacco sales, 547–548
- smokeless tobacco products, 549
- smoking prevention programs, 553, 555, 688
- social networking Web sites, 549–551
- summary, 551–552
- tobacco company Web sites, 548–549
  - expenditures on, 490, 493–494, 502–503, 546
- youth exposure to, 551
- direct mail advertising
  - expenditures on, 490, 492, 494, 501–502
  - increased use of, 508
- discount brands, 523–526, 547
- discounts. *See* price promotions
- Disney, 570
- disruptive disorders, 27–28
- dissolvable products, 155, 507, 540, 548
- distal factors, 509–511, 632–633
- Djarum (brand), 205
- dopamine pathway, 455
  - candidate genes, 26, 452
- drug use. *See* substance use; *specific drug*
- DSM-IV-TR*. *See* *Diagnostic and Statistical Manual of Mental Disorders*
- Duke, James Buchanan, 487
- Dutch Masters (brand), 205, 282, 284–285
- dynamic system, behavior as, 632
- dyslipidemia, 108–109
- dyspnea (shortness of breath), 88–94

## E

---

- Eastern Mediterranean (EMRO), tobacco use, 209–210
  - age of onset/ever smoked, 300–301, 407–408
  - current prevalence, 322–323, 332–333, 409–410
  - intensity of smoking, 311–312
  - smoking cessation, 322–323, 411–412
- eating disorders
  - initiation of smoking and, 68
  - smoking behavior and, 45, 56, 60–64
- Eating Disorders Inventory (EDI), 57, 63–64, 68
- eating habits, 196
- econometric studies
  - marketing-smoking link, 513–514
  - price-smoking link, 699–706
- EDI. *See* Eating Disorders Inventory
- educational levels
  - academic achievement (*See* academic achievement)
  - current smoking prevalence, 175, 177, 233, 436
  - smokeless tobacco use, 200–201, 271
  - smoking trend data, 189–190
  - tobacco use disparities, 153–154

- effect modification, 592
- Eight Men Out* (movie), 566
- Elaboration Likelihood Model of Persuasion, 636
- electronic cigarettes (e-cigarettes), 155, 549–551
- electronic technology
  - advertising (*See* digital marketing)
  - cessation programs using, 800–801, 807
- emotional response, to antismoking messages, 636, 686–689, 718, 810
- emphysema, 88
- employment levels. *See* socioeconomic status
- empowerment, youth, 789–792
- EMRO. *See* Eastern Mediterranean
- Ending the Tobacco Problem: A Blueprint for the Nation* (IOM), 4
- Ending the Tobacco Problem: A Tobacco Control Strategic Action Plan* (USDHHS), 854–856
- endogeneity, 714
- endorsements, expenditures on, 490, 501, 503
- endothelial dysfunction, 102–108
- entertainment media. *See* movie smoking; television advertising
- environmental factors
  - evidence summary, 458–459
  - genetic interaction with, 454–455
  - large environment
    - physical, 437–439, 458
    - social, 431–439, 458
  - marketing and, 509
  - protective, 631
  - retail stores, 541 (*See also* point-of-sale marketing)
  - small social groups, 439–445, 458–459
  - smoking prevention based on, 631–634
  - summary, 427–429
- environmental stream, 632–634
- environmental tobacco smoke. *See* clean air policies; secondhand smoke
- epidemiology
  - academic achievement, 161–162, 434–436
  - body weight, 157–161, 196–198, 265, 377–378
  - cigarette smoking
    - age at onset, 134–136, 164, 179–180, 190–191, 238, 244, 295–305
    - brand preferences, 161–164, 177–178, 190, 239–242, 366–367, 507
    - current prevalence, 135–139, 164, 174–175, 187–190, 229–233, 339–344, 363–364
    - developmental patterns, 179–185, 245–248, 344
    - disparities in, 149–154
    - ever smoked, 173–174, 185–186, 216, 227–228, 295–305, 345–349, 407–408
    - expectations to smoke, 183–184, 249–251
    - initiation of smoking, 142–143, 179–180, 261
    - intensity of smoking, 175–177, 180–181, 190, 234–237, 306–316, 365
    - knowledge and attitudes about, 191–192, 368–371
    - measures of, 215, 415–419

- prices, 526, 701–706
- projected rates, 854, 856
- smoking cessation, 191, 262, 317–327, 368
- substance use comorbidity, 193–194
- susceptibility to smoking, 179, 185, 243, 295–305
- trend data, 138–143, 185–191, 257–260, 294, 345–363
- cigar smoking
  - brand preferences, 164, 205, 282–286
  - current prevalence, 142, 145–146, 165, 203–205, 280–281, 374, 393–398
  - disparities, 154
  - ever used, 203, 279
  - measures of, 217, 421–423
  - prices, 155, 706
  - substance use comorbidity, 287
  - trend data, 149–151, 195, 205, 294, 399
- conclusions, 9, 165
- data analysis, 134
- data sources, 131–133, 210–214
- depression, 198, 266
- evidence summary, 164–165
- factors
  - gender (*See* gender)
  - racial/ethnic (*See* racial/ethnic groups)
  - socioeconomic (*See* socioeconomic status)
  - U.S. regional (*See* United States regional variations)
- health-related behaviors, 194–197, 372–381
- international statistics (*See* worldwide tobacco use)
- key measures, 133–134
- lung cancer, 188
- multiple tobacco product use, 154–155, 165, 205–209, 262, 276, 287, 289–290, 404–406
- nicotine addiction, 184–185, 252–256
- recent trends, 850–852
- smokeless tobacco use
  - age at onset, 201, 272, 291–293
  - brand preferences, 164, 201–202, 273–275, 277–278
  - current prevalence, 142, 144, 146, 164, 200–201, 269–271, 374, 382–388
  - disparities, 154
  - ever used, 199–200, 267–268, 392
  - measures of, 216–217, 419–421
  - multiple tobacco product use, 154–155, 165, 205–209, 276, 287, 289–290, 404
  - prices, 202, 706
  - substance use comorbidity, 193–194, 203
  - trend data, 144–149, 195, 202, 293–294, 389–392
- specialty cigarettes (bidis & kreteks)
  - measures of use, 217, 423–424
  - prevalence of use, 206–207, 288, 400–403
- substance use, 193–195, 203, 205–206
- suicidal ideation, 193–197, 376
- tobacco use measures, 215–217, 415–424
- violence, 193–197, 376–377
- ESPAD. *See* European School Survey Project on Alcohol and Other Drugs
- estimation equation, specification of, 713
- ethanolamines, 536
- ethnic groups. *See* racial/ethnic groups
- etiology of tobacco use
  - affective processes, 445–447, 451
  - cognitive processes, 447–451
  - conclusions, 10, 460
  - developmental stages, 429–430
  - evidence summary, 458–460
  - genetics (*See* genetic factors)
  - large environment
    - physical, 437–439
    - social, 431–439
  - multilevel influences, 459
  - neurobiological processes, 455–458
  - other forms of tobacco than cigarettes, 430
  - prenatal exposure, 457
  - small social groups
    - family, 443–445
    - peers, 439–443
  - smoking prevention theories based on, 631–632
  - summary, 427–429, 850–851
- Eunice Kennedy Shriver* National Institute of Child Health and Human Development, 212
- EURO. *See* Europe (EURO) region
- European School Survey Project on Alcohol and Other Drugs (ESPAD), 210, 337–338
- Europe (EURO) region
  - marketing practices, 531–532
  - tobacco use, 209–210, 337–338
    - age of onset/ever smoked, 301–303, 407–408
    - current prevalence, 323–325, 333–334, 409–410
    - intensity of smoking, 312–314
    - smoking cessation, 323–325, 411–412
- ever used
  - cigarettes, 173–174, 185–186, 227–228, 295–305, 345–349, 407–408
  - cigars, 203, 279
  - definitions of, 216–217, 415, 419, 421, 423
  - smokeless tobacco, 199–200, 267–268, 392
- evidence review methods, 7–8
- evidence summary
  - environmental factors, 458–459
  - epidemiology, 164–165
  - etiology of tobacco use, 458–460
  - health consequences, 110
  - marketing practices, 598–601
  - tobacco use prevention, 809–811
- executive function, 448
- exemplars, in antismoking strategy, 637
- exercise, 196, 379
- expectancy, 447
- expectations to smoke, 183–184, 249–251
  - cognitive and affective processes, 446–447
- experimentation stage, 430. *See also* initiation of smoking
- explicit cognitive factors, 447–448, 450–451
- extracurricular activities, 437, 455

## F

---

- Facebook, 549–551, 688
- Fagerström Test for Nicotine Dependence (FTND), 23–24, 454
- Fagerström Tolerance Questionnaire (FTQ), 23, 181  
modified for adolescents (mFTQ), 24
- Fairness Doctrine, 635, 684, 691
- family. *See also* parental behavior  
gene-environment interaction, 454–455  
influence of, 443–445, 631
- Family C.O.U.R.S.E. Consortium, 553
- family interventions, 720–727  
effectiveness of, 720–727  
ineffective programs, 726  
recommendations, 727  
study limitations, 726–727  
systematic reviews, 720–726
- self-help booklets, 552–553
- smoking cessation, 799–800
- theories underlying, 632–634, 720
- types of, 720
- Family Matters program, 725–726
- Family-School Partnership program, 721
- Family Smoking Prevention and Tobacco Control Act* (2009), 697  
advertising bans, 600  
brand descriptors, 697  
FDA authority established by, 4, 545, 810, 854  
health warnings, 719, 810  
online tobacco sales/marketing, 548  
product design and packaging, 205, 531, 534, 539, 541  
specialty cigarettes (bidis and kreteks), 207  
youth access, 810
- FCP. *See* Full Court Press
- FCTC. *See* Framework Convention on Tobacco Control
- FDA. *See* U.S. Food and Drug Administration
- Federal Communications Commission (FCC), 547, 635, 684
- federal taxes, 698–699. *See also* taxation
- Federal Trade Commission (FTC)  
marketing activities reported to, 488–494, 501–503, 507, 546, 715  
movie imagery investigation, 565
- FedEx, 548
- females  
advertising aimed at, 31, 519, 530–533  
epidemiology (*See* gender)  
increase in tobacco use by, 156  
smoking during pregnancy, 457 (*See also* prenatal exposure)  
Surgeon General's Report (2001) on, 4
- fetus  
DNA damage in, 21–22  
lipid levels in, 109  
low birth weight, 96, 108  
neurodevelopmental processes, 457, 459  
vascular injury in, 96–97
- films. *See* movie smoking
- filter ventilation, 531, 536–537
- financial incentives for retailers. *See* product placement
- Finland  
cardiovascular risk study, 101–102, 108  
family interventions, 721  
socioeconomic factors, 434
- Fire Safety Standards for Cigarettes Act* (2004), 697
- First Amendment protection, 564
- first use. *See* initiation of smoking
- “5 A's” model, 728, 731
- flavor additives  
in cigarettes, 537–539  
in electronic cigarettes, 549  
FDA ban on, 164, 178, 205, 207, 539  
menthol as, 178, 539  
in smokeless tobacco products, 539, 549
- flavored cigars, 155, 205
- Florida, tobacco control program, 694, 849, 853
- Focus on Kids (FOK) program, 725
- Food, Drug, and Cosmetic Act*, 853
- Food and Drug Administration. *See* U.S. Food and Drug Administration
- Foote, Emerson, 517–518
- forced-exposure studies, 558–563
- 4-H program, 555, 805
- Framework Convention on Tobacco Control (FCTC), 531, 545, 719
- France, respiratory disease, 91
- free nicotine levels, 539–541
- frequency of smoking. *See* intensity of smoking
- friends. *See* peer groups
- fruit flavoring. *See* flavor additives
- FTC. *See* Federal Trade Commission
- FTND. *See* Fagerström Test for Nicotine Dependence
- FTQ. *See* Fagerström Tolerance Questionnaire
- Full Court Press (FCP), 693

## G

---

- GABA (gamma amino butyric acid) pathway, 455
- GABA (gamma amino butyric acid) receptor genes, 452
- Garcia y Vega (brand), 283, 286
- gateway drug, tobacco as, 28–29, 193–194
- gender. *See also* females; males  
advertising campaigns, 519  
antismoking campaigns, 690
- cigarette smoking  
age of onset, 191, 295–305  
brand preferences, 163, 177–178, 239–242, 366–367, 536  
cultural influences, 433  
current prevalence, 136–138, 164, 174, 177, 229–232, 341–343, 363  
trends in, 187–189, 433
- disparities, 149, 152

- ever smoked, 173, 185–186, 227–228, 345–346, 349, 407–408
  - intensity of smoking, 175, 234–237
  - knowledge and attitudes, 192, 370
  - nicotine dependence, 184–185, 252–255
  - substance use comorbidity, 193, 263
  - susceptibility to smoking, 179, 243, 295–305
  - trajectories of smoking, 181–182, 245–248
  - trend data, 139–141, 143, 185–191, 257–261, 294, 345–346, 349
  - cigar smoking
    - brand preferences, 205, 282–283, 285–286
    - current prevalence, 142, 145–146, 149–151, 154, 165, 203–205, 280–281, 394, 396–398
    - ever used, 203, 279
    - trend data, 399
  - clinical interventions, 728
  - depression, 198, 266
  - family interventions, 726–727
  - lung cancer rates, 188
  - lung growth patterns, 80–85
  - movie smoking and, 569
  - multiple tobacco product use, 155, 165, 207–209, 276, 289–290, 404–406
  - peer group influences, 439
  - smokeless tobacco use
    - age of onset, 291–293
    - brand preferences, 273–274, 277–278
    - current prevalence, 142, 144–149, 164, 200–202, 269–270, 382–390
    - ever used, 199, 267–268
    - prevention programs, 802–804
    - prices, 706
  - social norms, 433, 438
  - specialty cigarettes (bidis & kreteks), 206–207, 288, 400–403
  - water pipes (hookahs), 206
  - weight control
    - beliefs about, 32–45
    - epidemiologic findings, 157–161, 197
    - initiation of smoking, 63–68
    - smoking behavior, 45–60
    - smoking cessation, 69, 75
  - worldwide tobacco use, 156, 158–159, 165, 209–210
    - age of onset/ever smoked, 295–305
    - current prevalence, 317–336, 409–410, 433
    - intensity of smoking, 306–316
    - smoking cessation, 317–327, 411–412
  - genetic factors, 451–453
    - definition of, 451
    - environmental interaction with, 454–455
    - evidence summary, 459
    - nicotine addiction, 25, 456–457
    - prenatal exposure, 21–22
    - pulmonary disease, 86
    - twin studies, 453–454
  - genetic linkage analyses, 451–452
  - genomewide association studies (GWAS), 452–453
  - genomic sequencing, 453
  - Germany
    - chronic respiratory disease, 91
    - marketing influences, 511
    - movie smoking, 575, 591, 598
  - gingival recession, 199
  - Global Adult Tobacco Survey, 210
  - Global Health Professions Students Survey, 210
  - Global School Personnel Survey, 210
  - Global Tobacco Surveillance System (GTSS), 156, 209–210
  - Global Youth Tobacco Survey (GYTS)
    - overview and methods, 131–133, 156, 209–211
    - age of onset, 295–305
    - current tobacco use, 156–157, 165, 209–210, 317–336, 409–410, 433
    - ever smoked, 295–305, 407–408
    - intensity of smoking, 306–316
    - other forms of tobacco than cigarettes, 413–414
    - smoking cessation, 317–327, 411–412
    - susceptibility to smoking, 295–305
    - tobacco use measures, 216
  - glucose intolerance, 109
  - Goldbrenner, Ronald S., 518
  - Good Behavior Game program, 791
  - Google, 550
  - graduation strategy, 539–540
  - Grizzly (brand)
    - market share, 164, 201–202, 273, 275, 277
    - product design, 540
  - gross rating points (GRPs), 684
  - Growing Up Tobacco Free: Preventing Nicotine Addiction in Children and Youths* (IOM), 4
  - growth mixture modeling, 180
  - GTSS. *See* Global Tobacco Surveillance System
  - Guiding Good Choices program, 725
  - GWAS. *See* genomewide association studies
  - GYTS. *See* Global Youth Tobacco Survey
- ## H
- 
- halitosis, 199
  - Handbooks of Cancer Prevention in Tobacco Control Volume 14* (IARC), 699
  - haplotypes, 452
  - Happy Days (brand), 540
  - Harley-Davidson USA, 518
  - Harvard School of Public Health College Alcohol Study, 709
  - HDL. *See* high-density lipoprotein
  - Health Belief Model, 636
  - health care providers. *See* clinical interventions
  - health consequences. *See also specific disease or symptom*
    - antismoking campaigns emphasizing, 635, 686–688
    - cardiovascular (*See* cardiovascular consequences)

- conclusions, 9, 111
  - from previous Surgeon General's Reports, 4, 15–21
- duration of smoking and, 22, 83
- early-life exposures, 21–22
- evidence summary, 110
- knowledge of (*See* knowledge of health consequences)
- nicotine addiction, 23–29 (*See also* nicotine addiction)
- respiratory (*See* respiratory consequences)
- smokeless tobacco use, 199, 427–428, 806, 808
- summary, 15
- warning labels (*See* health warnings)
- water pipes (hookahs), 207
- health-related behaviors, 194–197, 372–381, 633
- “Health Rocks” program, 555
- health warnings, 715–719
  - advertising bans and, 514
  - impact of
    - current text-based style, 715–716
    - “new” and rotating messages, 718
    - pictorial style, 717–719, 810
    - recommendations, 718–719, 810
    - by size and position, 716–717
  - packaging strategies and, 532, 535
  - requirements, 810
  - variations in, 715–716
- Healthy People 2010* (USDHHS), 5, 711
- Healthy People 2020* (USDHHS), 5, 135, 185, 854
- heart, physiological effects on, 97
- Heaviness of Smoking Index (HSI), 454
- Helping Youth Decide* booklet, 552–553
- herd brands, 521–522
- heritability. *See* genetic factors
- heterogeneity, 713–714
- Heuristic-Systematic Model, 636
- high-density lipoprotein (HDL) cholesterol, 108–109
- high-risk youth, antismoking campaigns for, 690–691
- Hispanic youth. *See* racial/ethnic groups
- Hoelter, Timothy K., 518
- home smoking policies, 709–710
- HONC. *See* Hooked on Nicotine Checklist
- Hong Kong, health consequences, 88, 102
- hookahs (water pipes), 155, 206–207, 430
- Hooked on Nicotine Checklist (HONC), 24, 456
- household-based sampling, 131, 215
- House of Menthol (Web site), 546
- housing, clean air policies, 710
- HSI. *See* Heaviness of Smoking Index
- humectants, 537
- Hungary, atherosclerosis, 100–101
- Hutchinson Smoking Prevention Project, 733, 789
- hypertension, 97, 199
- hypothesis testing, 8
- hypothesized endogenous variables, 592–593
- Hystar, 537
- IARC. *See* International Agency for Research on Cancer
- IAT. *See* Implicit Association Test
- Iceland, marketing practices, 534, 545
- ICVs. *See* Internet cigarette vendors
- identity-based peer groups, 441–443
- identity development, 564, 632–633
- illicit drugs. *See* substance use; *specific drug*
- imagery, 508, 519
  - on brand packaging, 530–533, 535
  - in entertainment media (*See* movie smoking; television advertising)
- IMBC. *See* Integrated Model of Behavior Change
- immigrants, cultural influences, 432–433
- ImPACT. *See* Informed Parents and Children Together
- IMPACT. *See* Initiatives to Mobilize for the Prevention and Control of Tobacco Use
- Implicit Association Test (IAT), 449
- implicit cognitive processes, 448–451
- incentives for retailers. *See* product placement
- income. *See* socioeconomic status
- India
  - family interventions, 721
  - movie smoking, 596
  - school-based programs, 786
  - tobacco use, 156, 433, 457
- individual heterogeneity, 713–714
- indoor air. *See* clean air policies
- inflammatory markers, 96
- informational approaches, 731
- Informed Parents and Children Together (ImPACT) program, 725
- inhalants, 193–194, 263, 276, 287
- initiation of smoking
  - age at (*See* age at onset)
  - current trends, 850
  - definitions of, 216–217, 417–418, 420, 422, 429
  - development of addiction from, 24–27, 429–430
    - epidemiology, 179–185, 245–248, 344
  - epidemiology, 142–143, 179–180, 261
  - genetic factors, 25–26, 456–457
    - twin studies, 453–454
  - marketing influences, 508, 512, 515–517, 599
  - packaging, 533
  - point-of-sale advertising, 544
  - pricing, 529, 704–705
  - product design, 535–539
  - mental health issues related to, 27–28
  - movie smoking and, 575, 590–591
  - multiple tobacco product use, 208–209
  - peer group influences, 439
  - prevention of (*See* smoking prevention)

risk factors for, 427–429, 632 (*See also* etiology of tobacco use)  
 stage model, 429–430  
 substance use risk, 29  
 trend data, 142–143, 261, 294  
 as weight control behavior, 63–68, 75–79  
 Initiatives to Mobilize for the Prevention and Control of Tobacco Use (IMPACT) program, 694, 696  
 “inserts” (package), 534  
 Institute of Medicine (IOM), 4, 695, 719, 785  
 insulin resistance, 109  
 integrated biopsychosocial-ecological models, 428, 631  
 Integrated Model of Behavior Change (IMBC), 636  
 intensity of smoking  
   definitions of, 216, 416–417  
   epidemiology, 175–177, 180–181, 190, 234–237  
     trend data, 365  
     worldwide statistics, 306–316  
   expectations to smoke and, 183–184, 249–251  
   genetic factors, 453–454  
   health consequences, 22, 83, 85  
   nicotine addiction and, 184, 429–430  
   pricing and, 702–704, 706  
   weight control beliefs, 42–43, 65–66  
 intentions to smoke  
   behavior linked to, 509, 512  
   marketing influences on, 512–513, 520, 543  
   movie smoking and, 596–598  
   smoking prevention programs and, 561, 687–689  
 interaction-based peer groups, 441–443  
 Interactive, Inc., 554  
 International Agency for Research on Cancer (IARC), 699  
 International Study of Asthma and Allergies in Childhood (ISAAC), 88, 91  
 international tobacco use. *See* worldwide tobacco use; *specific region or country*  
 Internet advertising. *See* digital marketing  
 Internet-assisted cessation programs, 800–801, 807  
 Internet cigarette vendors (ICVs), 547–548  
 intrapersonal factors, 428–429, 459, 509, 599  
 intrapersonal stream, 632–634  
 involuntary smoking. *See* secondhand smoke  
 IOM. *See* Institute of Medicine  
 Iowa Strengthening Families Program (ISFP), 725–726  
 Ireland  
   marketing practices, 545  
   respiratory disease, 88  
   weight control behavior, 57  
 ISAAC. *See* International Study of Asthma and Allergies in Childhood  
 ISFP. *See* Iowa Strengthening Families Program  
 Israel, respiratory disease, 91  
 “It’s the Law” program, 555–557

---

**J**


---

Japan, endothelial dysfunction, 102, 108  
 Japan Tobacco, 538  
 John Middleton Co., 539  
 Johnston, Myron, 527

---

**K**


---

Kessler, David, 849  
 Kessler, Gladys, 508, 521–522  
 Kickbutts program, 726  
 kinky oligopoly, 523  
 knowledge of health consequences  
   cognitive processes, 448  
   epidemiology, 191–192, 368, 392  
   health warnings and, 715–719  
   packaging and, 531–532  
   as risk factor, 427–428  
   smokeless tobacco use, 428, 806, 808  
 Kodiak (brand), 274–275, 277, 540  
 Kool (brand)  
   digital marketing, 546  
   market share, 366–367, 537  
   product design, 536, 538  
 Korea, weight control behavior, 59–60  
 kreteks  
   measures of use, 217, 423–424  
   prevalence of use, 206–207, 288, 402–403

---

**L**


---

labeling  
   brand descriptors, 31, 530–532, 697  
   public health (*See* health warnings)  
 large environment  
   physical, 437–438, 458  
   social, 431–437, 458  
 latent class analysis (LCA), 182  
 latent transition analysis (LTA), 182  
 LCA. *See* latent class analysis  
 LDL. *See* low-density lipoprotein  
 learning, cognitive-behavioral principles of, 447–448  
 LeBow, Bennett S., 518  
 left ventricular mass, 97  
 legislation. *See* regulation; *specific law*  
 Leo Burnett, 520  
 leukoplakia, 199  
 Levi Garrett, 273, 275, 278

LifeSkills Training (LST) program, 554–555, 725–726, 785, 791  
Liggett Group, LLC, 488, 518, 566  
“light” descriptors, 531–532, 697  
lingering effects, of advertising, 713  
linkage analyses (genetic), 451–452  
lipids, 108–109  
literacy skills, health warnings and, 718–719  
little cigars (kreteks)  
    measures of use, 217, 423–424  
    prevalence of use, 206–207, 288, 402–403  
local governments  
    clean air policies, 707–710  
    taxes, 699 (*See also* taxation)  
    youth access laws, 710–712, 810  
logos, on packaging, 530, 532–533  
Longhorn, 275  
Lorillard Tobacco Company, 488, 518–519  
    brand-specific advertising, 521  
    Newport brand (*See* Newport)  
    smoking prevention programs, 553, 557, 635  
low birth weight, 96, 108  
low-density lipoprotein (LDL) cholesterol, 109  
low-income neighborhoods. *See also* socioeconomic status  
    tobacco marketing in, 542–543  
“low tar” descriptors, 531–532, 697  
LST. *See* LifeSkills Training  
LTA. *See* latent transition analysis  
Lucky Strike (brand), 31, 565–566  
Lund, Nancy B., 520  
lung cancer, 188  
lung function, 80–86  
    gender patterns, 80–85  
    intensity of smoking, 83, 85  
    summary, 86–87

## M

---

magazine advertising, expenditures on  
    cigarettes, 489, 491–493  
    smokeless tobacco, 501–502  
maillard browning process, 535  
males  
    advertising aimed at, 519  
    epidemiology (*See* gender)  
marijuana use  
    nicotine addiction and, 184–185, 252–255  
    prevalence of, 194–195, 373  
    tobacco use comorbidity, 193–194, 203, 205–206, 263–264,  
    276, 287, 371  
    tobacco use risk, 28–29  
marketing practices  
    advertising (*See* advertising)  
    brand-specific, 161–164, 177, 507, 516–521  
    conceptual framework, 509–511  
    conclusions, 10, 601–602  
    definition of, 713

entertainment media (*See* movie smoking; television advertising)  
evidence summary, 598–601  
expenditures on, 488–507, 541, 546, 715, 852  
    cigarettes, 488–500  
    smokeless tobacco, 491, 501–507  
impact of, 438, 487, 508–509, 599  
    awareness of smoking, 511–512  
    brand preferences, 516  
    initiation of smoking, 508, 512, 515–517, 529, 533,  
    535–539, 544  
    intentions to smoke, 512–513, 520, 543  
    peer pressure, 519–522  
    smoking behavior, 513–517, 520  
    systematic reviews, 516–517  
Internet (*See* digital marketing)  
packaging (*See* packaging)  
point-of-sale (*See* point-of-sale marketing)  
prices (*See* pricing)  
product design, 535–541  
promotions (*See* promotional activities)  
regulation of (*See* advertising bans)  
summary, 487, 508–509, 851–852  
tobacco industry position on, 517–522  
types of, 488–491  
women as target of, 31, 519, 530–533  
young adults as target of, 508, 518–522  
market-level data, validity of, 713  
Marlboro (brand)  
    brand-specific marketing, 516, 518–521  
    market share, 161–164, 177–178, 190, 239–242, 366–367,  
    507, 850  
    Marlboro Man persona, 511–512, 518  
    Marlboro Snus, 507  
    point-of-sale advertising, 529  
    price promotions (“Marlboro Friday”), 488, 523–525  
    product design, 535–537  
    retail-value-added promotions, 491  
    Web site, 546, 548  
masking agents, 535–539  
Massachusetts, tobacco control program, 694, 849  
Massachusetts Prevalence Study, 802  
mass media advertising. *See also* movie smoking; television advertising  
    ban on, 507, 566, 574, 635  
    econometric analyses of, 514  
mass media antismoking campaigns, 635–692  
    audience segmentation, 689–691  
    content and formats, 686–688  
    context, 689  
    effectiveness of, 637–686  
        controlled exposure studies, 558–563, 637–646, 683–684  
        naturalistic exposure studies, 558, 561–562, 669–682,  
        686–688  
        population-based studies, 647–668, 684–686  
    history of, 635  
    industry-sponsored, 557–563, 635, 687  
    intensity and duration, 688–689

- optimizing factors, 686–691
- review methodology, 636–637
- summary, 691–692, 809
- theoretical implications, 691
- theories underlying, 633–634, 636–637
- “truth” ads, 558, 561, 635, 687–690, 850
- Master Settlement Agreement (1998), 4, 850
  - advertising bans, 437, 487, 714–715, 810
  - entertainment media imagery since, 564
  - marketing expenditures since, 488–491, 507–508
  - movie imagery since, 566–567
  - non-participating manufacturers (NPMs), 525–526
  - original participating manufacturers (OPMs), 525–526
  - point-of-sale marketing since, 541–544, 600
  - pricing since, 513–514, 525–528, 530
  - product design since, 538
  - Smokeless Tobacco, 507
  - smoking trends since, 139–141, 185, 191, 515–516, 852
  - subsequent participating manufacturers (SPMs), 525–526
  - taxes and, 699
  - tobacco control funding, 554, 694, 852–853
- maternal smoking. *See* parental smoking; prenatal exposure
- Maxwell Report, 275, 284
- McCann-Erickson, 517
- measurement error, 713
- measures of tobacco use, 215–217, 415–424
- Media Campaign Resource Center (CDC), 636
- mediational pathways, 592–593
- medical settings. *See* clinical interventions
- memory associations, 449
- Memory Association Test, 449
- Memphis Health Project, 32, 56, 65, 68
- mental health, 27–28
- mentholated cigarettes, 537–539. *See also specific brand*
  - brand preferences, 161, 177–178, 190, 537
  - cultural influences on use of, 432, 543
  - effect on lung function, 83–86
  - as flavoring, 178, 207, 539
  - initiation of smoking with, 535, 538–539
  - product design, 537
  - use by young smokers, 538–539
- Merlo, Ellen, 554
- mesocorticolimbic dopamine system, 455
- metropolitan statistical areas (MSAs)
  - current smoking prevalence, 175, 233, 271
  - smokeless tobacco use, 201
- Mexico, movie smoking, 575, 591, 598
- MI. *See* myocardial infarction
- Midwestern Prevention Project (MPP), 725, 785, 791
- “mild” descriptors, 531–532, 697
- Minnesota, tobacco control program, 694, 849, 853
- Minnesota Adolescent Community Cohort Study, 709
- Minnesota Class of 1989 Study, 726, 785
- Minnesota Heart Health Program, 637, 726
- Minnesota Smoking Prevention Program, 791
- Minnesota Student Survey, 58
- minority groups. *See* racial/ethnic groups
- Mississippi, tobacco control program, 694, 849, 853
- mobile telephones, cessation programs using, 801, 807
- moderate-to-vigorous physical activity (MVPA), 196
- moderation effects, 592
- moist snuff. *See* smokeless tobacco
- Monitoring the Future (MTF): A Continuing Study of American Youth
  - overview and methods, 131–133, 211–212
  - academic achievement, 161–162
  - cigarette smoking
    - current prevalence, 174–175, 187–189, 229–230, 233
    - ever smoked, 173–174, 185–186, 227–228, 345–346
    - expectations to smoke, 183–184, 249–251
    - initiation of smoking, 180, 244, 704
    - intensity of smoking, 175–177, 190, 236–237, 365
    - intentions to smoke, 512–513
    - prices, 702, 704–706
    - smoking cessation, 368
    - substance use comorbidity, 193, 263–264, 276, 371
    - trend data, 138–142, 164, 185–191, 257, 345–353
  - cigar smoking, 149
  - clean air policies, 709
  - marketing exposure, 529, 561
  - movie smoking, 567–569
  - multiple tobacco product use, 207–209, 262, 276, 289–290
  - perceived health risks, 191–192, 368, 392
  - perceptions of smoking, 192, 369–371
  - school tobacco policies, 788
  - smokeless tobacco use
    - age at onset, 201, 291
    - ever used, 199–200, 267–268
    - prevalence, 145, 147, 164, 200–202, 269–271, 389–392
    - substance use comorbidity, 203, 276, 371
  - substance use comorbidity, 193, 263–264, 276, 371
  - tobacco control funding, 696
  - tobacco use disparities, 149, 153
  - tobacco use measures, 216–217, 415–424
- mood, 445–447
- Motion Picture Association of America (MPAA), 570, 598
- motivational approaches, 731
- Mountain Dew (brand), 548
- movie smoking, 565–598
  - content analysis, 566, 571–574
  - depictions of smoking, 567–570
  - as environmental factor, 437–438
  - experimental research, 596–598
  - exposure assessment, 571–574
  - historical links between tobacco industry and, 565–566
  - identity development and, 564
  - media company responses, 570–571
  - movie ratings, 564, 569–571, 574, 593–596, 598
  - movie stars as role models, 564, 571, 597
  - movie trailers, 571
  - population-based research, 575–596
    - cross-sectional studies, 575, 593
    - longitudinal studies, 575–592
    - mediation pathways, 592–593

- moderation effects, 592
- parental control over media exposure, 593–596
  - summary, 593
- product placement, 565–567
  - as stream of influence, 511
  - summary, 598, 601, 852
- MPAA. *See* Motion Picture Association of America
- MPP. *See* Midwestern Prevention Project
- MSAs. *See* metropolitan statistical areas
- MTF. *See* Monitoring the Future
- multilevel models, 459
- multiple-baseline studies, 634
- multiple tobacco product use
  - current trends, 850
  - epidemiology, 154–155, 165, 205–209, 262, 276, 287, 289–290, 404–406
- MVPA. *See* moderate-to-vigorous physical activity
- myocardial infarction (MI), 199
- My Smokers' Rights (Web site), 548–550
- MySpace, 550, 688

## N

---

- nAChRs. *See* nicotinic acetylcholine receptors
- narratives, in antismoking strategy, 637
- National Association of State Boards of Education (NASBE), 552–553
- National Cancer Institute (NCI)
  - ASSIST, 694, 696, 786
  - COMMIT, 693
    - smoking prevention criteria, 553
    - tobacco control monographs, 5, 23, 26, 517, 564, 601, 715, 852
    - Youth Smoking and the Media study, 558, 636–637, 686–688, 691
- National Center for Chronic Disease Prevention and Health Promotion (CDC), 7
- National Center for Health Statistics (CDC), 212
- National Education Longitudinal Study (NELS), 703–705
- National Health and Nutrition Examination Survey (NHANES), 197, 707, 710
- National Health Interview Survey (NHIS)
  - overview and methods, 132–134, 212
  - body mass index, 197
  - smoking trend data, 141–142, 188–189, 258–260, 359–363
- National Heart, Lung, and Blood Institute Growth and Health Study, 64
- National Institute on Drug Abuse (NIDA), 539
- National Institutes of Health (NIH), 554, 854
- National Longitudinal Study of Adolescent Health (Add Health)
  - overview and methods, 132–134, 212
  - socioeconomic factors, 434
  - stages of smoking behavior, 182–183, 246–248
  - trajectories of smoking, 180–181, 245–247, 344
  - weight control behavior, 66
- National Longitudinal Survey of Youth (NLSY), 66, 703–704
- National Registry of Evidence-based Programs and Policies, 791
- National Smokers Alliance, 550
- National Survey on Drug Use and Health (NSDUH)
  - overview and methods, 131–133, 213
  - cigarette smoking
    - age at onset, 134–136, 179–180, 191, 238, 244
    - brand preferences, 161, 163, 177–178, 190, 241–242, 366–367
    - current prevalence, 137–139, 164, 174–175, 229–232, 339–344, 363–364
    - ever smoked, 173–174, 227–228
    - initiation of smoking, 179–180, 261
    - intensity of smoking, 175–177, 234–237
    - nicotine dependence, 184–185, 252–256
    - trend data, 138–143, 185–191, 294
  - cigar smoking
    - brand preferences, 282–283, 285–286
    - current prevalence, 142, 146, 149, 151, 203–205, 280–281, 393–398
    - ever used, 203, 279
    - substance use comorbidity, 287
  - clean air policies, 709
  - depression, 198, 266
  - multiple tobacco product use, 276, 287, 289–290, 404
  - smokeless tobacco use
    - age of onset, 291–293
    - brand preferences, 273–274
    - current prevalence, 142, 145–146, 148–149, 200–202, 269–270, 382–388
    - ever used, 199–200, 267–268
    - substance use comorbidity, 203, 276
  - susceptibility to smoking, 179, 185, 243
  - tobacco use disparities, 149–154
  - tobacco use measures, 216–217, 415–424
- National Tobacco Control Program, 694, 696
- National Youth Risk Behavior Survey. *See* Youth Risk Behavior Survey (YRBS)
- National Youth Tobacco Survey (NYTS)
  - overview and methods, 131–133, 213–214
  - cigarette smoking
    - age at onset, 244
    - current prevalence, 135, 137, 139, 229–230
    - ever smoked, 173–174, 227–228
    - intensity of smoking, 234–237
    - mentholated cigarettes, 178
    - trend data, 138–142
  - cigar smoking
    - ever used, 203, 279
    - prevalence, 142, 145, 149, 203–205, 280–281
    - prices, 706
  - digital marketing exposure, 551
  - multiple tobacco product use, 155, 207–209, 289–290
  - smokeless tobacco use
    - age at onset, 201, 272
    - current prevalence, 142, 144, 200–201, 269–270
    - ever used, 199–200, 267–268

- specialty cigarettes (bidis & kreteks), 206–207, 288, 400–403  
tobacco use measures, 216–217, 415–424
- Native Americans. *See* American Indians
- naturalistic exposure studies, 558, 561–562, 669–682, 686–688
- NCI. *See* National Cancer Institute
- NDSS. *See* Nicotine Dependence Syndrome Scale
- negative affect, 445–447, 451
- neighborhoods  
socioeconomic factors, 434  
tobacco outlets in, 436–437
- NELS. *See* National Education Longitudinal Study
- Netherlands  
health warnings, 717  
lung function studies, 83
- neurobehavioral systems, 428
- neurobiological processes, 451, 455–459
- neurodevelopmental processes, 451, 456–459
- neurotransmission  
candidate gene studies, 452  
effects of nicotine on, 455–456, 459
- neurotrophic tyrosine kinase receptor type 2 (*NTRK2*) gene, 452
- Newport (brand)  
ad campaigns, 519, 521, 537  
market share, 161–164, 177–178, 190, 239–242, 366–367, 507, 537, 850  
point-of-sale advertising, 529
- newspaper advertising, expenditures on  
cigarettes, 489, 491–493  
smokeless tobacco, 501–502
- New York Tobacco Control Program (NYTCP), 696–697, 853
- New Zealand  
marketing practices, 513, 532  
movie smoking, 598  
respiratory disease, 94  
socioeconomic factors, 434  
weight control behavior, 45
- NHANES. *See* National Health and Nutrition Examination Survey
- NHIS. *See* National Health Interview Survey
- nicotine addiction, 23–29  
clinical diagnosis of, 23–24  
development of, 24–27, 429–430  
epidemiology, 179–185, 245–248, 344  
epidemiological patterns, 184–185, 252–256  
genetic factors, 25–26, 451–453, 456–457  
measurement of, 23–24, 456  
neurobiological effects of, 451, 455–459  
product design enhancing, 535–539  
withdrawal symptoms, 23–24, 456
- Nicotine Dependence Syndrome Scale (NDSS), 24, 184
- nicotine metabolism, genetic influences on, 26, 452
- nicotine replacement therapy, 635, 800, 807
- Nicotine & Tobacco Research*, 177
- nicotinic acetylcholine receptors (nAChRs), 455
- nicotinic receptor genes, 452
- NIDA. *See* National Institute on Drug Abuse
- nightclubs, promotional activities in, 522, 534
- NIH. *See* National Institutes of Health
- NLSY. *See* National Longitudinal Survey of Youth
- noncurrent established smokers, 430
- noncurrent experimenters, 430
- non-participating manufacturers (NPMs), 525–526
- nonsusceptible stage, 430
- norms (social)  
large social environment, 431–433, 437–439, 509  
peer group, 443  
smoking prevention and, 632, 635, 686–690
- North Carolina Youth Empowerment Study, 790
- North Karelia Youth Project (Finland), 637, 692, 785
- Norway  
family interventions, 721, 726  
marketing influences, 512  
respiratory disease, 91
- Not On Tobacco (N-O-T) program, 800–801
- NPMs. *See* non-participating manufacturers
- NSDUH. *See* National Survey on Drug Use and Health
- NTRK2*. *See* neurotrophic tyrosine kinase receptor type 2 gene
- nutrition, 196, 379–380
- NYTCP. *See* New York Tobacco Control Program
- NYTS. *See* National Youth Tobacco Survey

---

**O**

- obesity, 196–198, 377–378  
prevention of (*See* weight control)
- OECD. *See* Organisation for Economic Co-Operation and Development
- Office of Applied Studies (SAMHSA), 213
- Office on Smoking and Health (CDC), 7
- oligopoly, 523
- online marketing. *See* digital marketing
- online tobacco sales, 547–548
- “onserts” (package), 534
- onset of smoking. *See* initiation of smoking
- open source marketing, 548
- OPMs. *See* original participating manufacturers
- oppositional defiant disorder, 27–28
- oral cancer, 199, 806, 808
- Oregon, tobacco control program, 694
- Oregon Research Institute, 803
- Oregon Social Learning Center, 720
- Organisation for Economic Co-Operation and Development (OECD), 514
- organized activities, 437, 455
- original participating manufacturers (OPMs), 525–526
- outdoor advertising  
antismoking messages, 688  
tobacco industry expenditures on  
cigarettes, 489, 491–493  
smokeless tobacco, 501–502
- oxidative stress, 95–96

**P**

- packaging, 530–535
  - imagery on, 530–533, 535
  - industry expenditures on, 488, 507
  - links to other marketing, 533–535
  - plain (standardized), 532–533
  - in response to tobacco control, 534–535
  - risk perception and, 531–532
  - shape and size, 533–535
  - smokeless tobacco products, 531, 533, 540–541
  - summary, 535, 599–600
  - warnings on (*See* health warnings)
- PAHO. *See* Americas (PAHO)
- Pall Mall (brand), 535
- parental behavior. *See also* family
  - control over media exposure, 593–596
  - gene-environment interaction, 454–455
  - home smoking policies, 709–710
  - influence of, 444, 519–520, 553, 720
- parental education
  - as cultural influence, 433–434
  - current smoking prevalence by, 175, 233
  - smokeless tobacco use, 200–201, 271
  - smoking trend data by, 189
  - tobacco use disparities by, 153
- parental smoking
  - health effects of (*See* prenatal exposure; secondhand smoke)
  - movie smoking and, 592
  - psychosocial influence of, 443–445
- parenting style, 444
- Parent on Your Side program, 721
- “Parents. The Best Thing Between Kids and Cigarettes”
  - campaign, 557
- Parliament (brand), 521
- passive smoking. *See* secondhand smoke
- Pathobiological Determinants of Atherosclerosis in Youth (PDAY), 97–102
- patterns of smoking. *See* intensity of smoking
- PayPal, 548
- PDAY. *See* Pathobiological Determinants of Atherosclerosis in Youth
- peer groups
  - versus* family context, 444–445
  - gene-environment interaction, 454
  - homogeneity of tobacco use, 439–441, 520
  - interaction-based *versus* identity-based, 441–443
  - marketing interplay with, 519–522, 599
  - movie smoking and, 592–593
  - smoking prevention, 632–633, 786
    - school environment (*See* school-based programs)
    - youth empowerment and activism, 789–792
- PepsiCo, 548
- perceived health risks
  - cognitive processes, 448
  - epidemiology, 191–192, 368, 392
  - health warnings and, 715–719
  - packaging and, 531–532
  - as risk factor, 427–428
  - smokeless tobacco use, 428, 806, 808
    - smoking prevention programs and, 561
  - perceptions of smoking. *See* attitudes toward smoking
  - periodontal disease, 199
  - peripheral processing systems, in communication theory, 636
  - personality traits, 632
  - personal risk factors, 427, 632–634
  - persuasion, communication theories of, 636, 686
  - PFDY. *See* Preparing for the Drug Free Years program
  - pharmacies, point-of-sale advertising in, 545
  - pharmacologic adjuncts for cessation, 635, 800, 807
  - phenotypes
    - definition of, 451
    - genomic sequencing, 453
    - initiation of smoking affected by, 26
    - twin studies, 453–454
  - Phenotypes and Endophenotypes: Foundations for Genetic Studies of Nicotine Use and Dependence* (NCI Monograph 20), 23, 26
  - Philip Morris, 488
    - brand-specific marketing, 516, 520–522
    - corporate website, 546, 548, 553
    - digital marketing, 547–548
    - Marlboro brand (*See* Marlboro)
    - packaging strategies, 534
    - Parliament brand, 521
    - pricing strategies, 523–525, 527
    - product design, 535–539
    - promotional allowances, 491, 542
    - smokeless tobacco products, 539–540
    - smoking prevention programs, 553–555
      - mass media, 557–563, 635, 687
      - youth access, 555–557
  - Phillies (brand), 205, 282, 284–285
  - pH modifiers, 539, 541
  - physical activity, 196, 379
  - physical environment, large, 437–438, 458
  - pictorial health warnings, 717–719, 810
  - Pinkerton Tobacco Co., 548. *See also* Red Man
  - pipe tobacco, taxes on, 698
  - pipe use, 430, 454
  - plain packaging, 532–533
  - plasticity of development, 632
  - point-of-sale marketing, 541–545
    - adolescent tobacco use linked to, 544
    - bans on, 534, 545
    - convenience stores, 543–544
    - density of retail outlets, 544–545
    - as environmental risk factor, 437
    - expenditures on, 489, 491–493, 501–502, 541
    - packaging as, 534
    - policy options, 545
    - price promotions, 528–529
    - product location, 542
    - summary, 545, 600

- Pollay, R.W., 521
- population density
  - current smoking prevalence, 175, 233, 271
  - smokeless tobacco use, 201
- population surveys. *See also specific survey*
- validity of, 215
- Portugal, academic achievement, 161
- possession, use, and purchase (PUP) laws, 696, 702, 711–712
- postmortem studies, atherosclerosis, 97–101
- poverty. *See socioeconomic status*
- powerwalls, 534
- precontemplation stage, 430
- prenatal exposure
  - DNA damage, 21–22
  - lipid levels, 109
  - low birth weight, 96, 108
  - neurodevelopmental processes, 457, 459
  - vascular injury, 96–97
- preparation stage, 430
- Preparing for the Drug Free Years (PFDY) program, 725–726
- prevalence. *See epidemiology*
- Prevent all Cigarette Trafficking Act* (2009), 548
- prevention programs. *See also specific program*
  - cigarette smoking (*See smoking prevention*)
  - conclusions, 10, 812
  - evaluation methods, 213, 558–561, 633–634, 636
  - evidence summary, 809–811
  - smokeless tobacco use, 801–804
- price discrimination, 528
- price elasticity of demand, 699–706
- price leadership, 523
- price promotions
  - definition of, 713
  - impact on tobacco use, 528–529
  - industry expenditures on
    - cigarettes, 488–494, 497–500
    - smokeless tobacco, 501–503, 505–506
  - in response to tobacco control, 527–528
  - tax increases and, 526–527
- pricing, 522–530
  - cigars, 155, 706
  - impact on tobacco use, 528–529, 699–706, 809
  - initiation of smoking, 529, 704–705
  - intensity of smoking, 702–704, 706
  - smoking cessation, 705
  - smoking prevalence, 526, 701
  - marketing expenditures and, 488
  - in response to tobacco control, 527–528
  - sales data by price, 525
  - sensitivity of youth smokers to, 527–528, 534–535, 699–706
  - since Master Settlement Agreement, 513–514, 525–528, 530
  - smokeless tobacco, 202, 706, 802
  - strategies, 523–528
  - summary, 529–530, 851
  - taxes and, 523–524, 526–527, 699–707
- Pride Surveys, 720
- Prime Time Little Cigars (brand), 283
- print advertising, expenditures on
  - cigarettes, 489, 491–493
  - smokeless tobacco, 501–502
- processing systems, in communication theory, 636
- Pro-Children Act* (1994), 788
- product design. *See also packaging*
  - cigarettes, 535–539, 600
  - smokeless tobacco, 539–541, 600
  - summary, 541, 851
- product labeling
  - brand descriptors, 31, 530–532, 697
  - public health (*See health warnings*)
- product placement (promotional allowances)
  - definition of, 713
  - expenditures on
    - cigarettes, 489, 491–493, 497–500
    - smokeless tobacco, 501–502, 505–506
  - movies, 565–567
  - retail outlets, 542, 600
  - summary, 852
- Programs to Advance Teen Health, 802
- Project CHIPS (Choosing Healthy Influences for a Positive Self), 787
- Project FLAVOR (Fun Learning about Vitality, Origin, and Respect), 787
- Project MYTRI, 786
- Project SHOUT (Students Helping Others Understand Tobacco), 785, 803
- Project SixTeen, 802
- Project SMART (Self-Management and Resistance Training), 787, 789
- Project STAR (Students Taught Awareness and Resistance) program, 725
- Project Towards No Tobacco Use (TNT), 791, 803
- promotional activities, 508–522. *See also marketing practices*
  - bans on (*See advertising bans*)
  - in bars and nightclubs, 522, 534
  - definition of, 713
  - expenditures on
    - cigarettes, 490–493, 495–496
    - smokeless tobacco, 501–507
  - initiation of smoking and, 515–516
  - “Marlboro Friday,” 488, 523–525
  - movie tie-ins, 565
  - on packaging, 534
  - summary, 487, 508–509, 851–852
- prosmoking Web sites, 548–551
- protective factors, 428, 444, 509, 631
- proximate factors, 509–511, 632–633
- psychiatric disorders, 27–28, 195–196
- psychosocial approaches, 731
- psychosocial risk factors, 427
- public entertainment sponsorships
  - bans on, 491, 534
  - expenditures on
    - cigarettes, 490–492, 494, 497–500
    - smokeless tobacco, 501–507
  - promotion of, 534

*Public Health Cigarette Smoking Act* (1969), 547  
public housing, clean air policies, 710  
public spaces, smoking in. *See* clean air policies  
puffed tobacco filler, 537  
puffers, 430  
pulmonary function. *See* lung function; respiratory consequences  
pulsing technique, 713  
PUP. *See* possession, use, and purchase laws

## Q

---

quality-adjusted life year (QALY), 791  
quitting  
cigarettes (*See* smoking cessation)  
smokeless tobacco use, 804–808

## R

---

R.J. Reynolds Tobacco Company (RJR). *See* Reynolds American, Inc.  
racial/ethnic groups  
antismoking campaigns, 690  
cardiovascular consequences, 109  
cigarette smoking  
age of onset, 191  
brand preferences, 161, 177–178, 239–242, 537  
current prevalence, 136–138, 164, 174–175, 177, 229–232, 364  
trends in, 187–190, 352–353  
disparities, 149–154  
ever smoked, 173–174, 186, 227–228  
intensity of smoking, 176, 234–237  
knowledge and attitudes, 192, 370  
nicotine dependence, 184–185, 252–255  
susceptibility to smoking, 179, 243  
trajectories of smoking, 181–182, 245–247  
trend data, 139–143, 185–191, 257–261, 294, 347–348, 359–363  
cigar smoking  
brand preferences, 205, 282–283, 285–286  
current prevalence, 142, 145–146, 149–151, 154, 165, 203–205, 280–281, 395  
ever used, 203, 279  
trend data, 399  
clean air policies, 707  
clinical interventions, 728  
cultural influences, 432–433  
depression, 198, 266  
family context, 444  
lung cancer rates, 188  
movie smoking, 569, 575, 591–592  
multiple tobacco product use, 155, 165, 207–209, 289–290, 405–406

peer group influences, 439  
point-of-sale marketing and, 542–543  
price sensitivity, 705  
respiratory consequences, 83–86, 88  
school-based programs, 787  
smokeless tobacco use  
age of onset, 291–293  
brand preferences, 273–274, 277–278  
current prevalence, 142, 144–149, 164, 200, 202, 269–270, 387, 391–392  
ever used, 199–200, 267–268  
prevention programs, 803–804  
specialty cigarettes (bidis & kreteks), 206–207, 288, 400–403  
Surgeon General's Report (1998) on, 4  
weight control  
beliefs about, 32–43  
epidemiologic findings, 157–161, 197–198  
initiation of smoking, 67, 79  
smoking behavior, 56–58  
smoking cessation, 69, 75  
youth access, 712

*Racketeer Influenced and Corrupt Organizations (RICO) Act* (1970), 508

radio  
advertising ban, 635  
antismoking messages, 635, 688  
*Raising Kids Who Don't Smoke* (brochure), 553  
randomized controlled trials (RCTs)  
advertising impact, 713–714  
movie smoking impact, 597–598  
smokeless tobacco use prevention, 802, 807  
smoking prevention, 634, 692–693  
cessation programs, 793, 800  
clinical interventions, 730  
family interventions, 721–727  
school-based programs, 732–734, 786  
“Real Parents. Real Answers” program (Web site), 553  
recall studies  
antismoking campaigns, 686–689  
health warnings, 715–718  
movie smoking, 571, 575  
recent acquisition stage, 430  
Red Man (brand)  
market share, 201, 273, 275, 277  
Web site, 548  
Red Seal (brand), 273, 275, 277  
refusal skills training program (Biglan), 726  
regional variations. *See* United States regional variations  
regulation. *See also specific law*  
advertising bans (*See* advertising bans)  
clean air (*See* clean air policies)  
international, 854  
public health (*See* health warnings)  
recommendations, 853–856  
taxes (*See* taxation)  
tobacco control (*See* tobacco control policies)  
youth access, 710–712, 810

relative improvement (RI) rates, 721–726, 785

religion

- influence on smoking behavior, 431–432
- smokeless tobacco use and, 201, 271
- smoking prevalence and, 175, 233, 431–432

replicated moderation effects, 592

respiratory consequences, 79–94

- chronic symptoms and diseases, 87–94 (*See also specific disease or symptom*)
- evidence review methods, 80
- genetic factors, 86
- lung growth, 80–87

retail outlets

- advertising in (*See point-of-sale marketing*)
- convenience stores, 543–544
- density of, 437, 544–545
- online tobacco sales, 547–548
- prices (*See pricing*)
- in school neighborhoods, 436–437, 529, 543–545
- youth access, 555–557, 710–712, 810

retail-value-added promotions. *See price promotions*

Revel (brand), 533

reverse causality, 714

reward pathways, 455–456

Reynolds American, Inc., 488

- brand-specific marketing, 516
- Camel brand (*See Camel*)
- corporate website, 546, 548
- digital marketing, 546–550
- Kool brand (*See Kool*)
- Pall Mall brand, 535
- pricing strategies, 524, 528
- product design, 535–539
- Salem brand, 537
- smokeless tobacco products, 539–540
- Tempo brand, 521
- Uptown brand, 537
- Winston brand, 535–536

RI. *See relative improvement rates*

RICO. *See Racketeer Influenced and Corrupt Organizations Act*

risk factors

- substance use, 28–29
- tobacco use, 427–429 (*See also etiology of tobacco use; specific factor*)
  - marketing influence, 509–511
  - smoking prevention based on, 631–632

risk profile, 428

RJR. *See R.J. Reynolds Tobacco Company*

Roberts, Peggy, 557

Robert Wood Johnson Foundation, 694

*The Role of the Media in Promoting and Reducing Tobacco Use* (NCI Monograph 19), 5, 517, 564, 601, 715, 852

Romania, school-based programs, 786

Romeo y Julieta (brand), 285

Rudman, Warren B., 556

rural areas

- current smoking prevalence, 175, 233, 271
- smokeless tobacco use, 201

## S

---

Salem (brand), 537–538

sales. *See retail outlets*

SAMHSA. *See Substance Abuse and Mental Health Services Administration*

sampling, expenditures on

- cigarettes, 489, 491–493
- smokeless tobacco, 501, 503

Santa Fe Natural Tobacco Company, Inc., 488

Satcher, David, 853

Scandinavian Asthma Genetic Study, 86

schizophrenia, 27–28

school-based programs, 731–792

- approaches used in, 731–732
- cost-effectiveness of, 791
- effectiveness of, 731–732
  - antitobacco policies, 787–788
  - cultural sensitivity, 787
  - evidence-based practice, 787
  - ineffective programs, 788–789
  - meta-analyses, 732–734
  - recent studies, 786
  - short- and long-term effects, 734–786
  - summary, 786–787, 811
- evaluation methods, 634
- industry-sponsored, 554–555
- smokeless tobacco use, 802–807
- smoking cessation, 799–800
- summary, 791–792, 811
- theories underlying, 633–634
- youth empowerment and activism, 789–792

school-based surveys. *See also specific survey*

- data collection methods, 131
- validity of, 215

school environment, 435–437

- antitobacco policies, 435, 707–709, 787–788
- gene-environment interaction, 455
- neighborhood tobacco outlets, 436–437, 529, 543–545
- peer social networks within, 441–442

School Health Policies and Programs Study (CDC), 435

SCQ. *See Smoking Consequences Questionnaire*

scientific reviews, 4–5. *See also specific review*

screening. *See clinical interventions*

SEARO. *See South-East Asia*

secondhand smoke

- cardiovascular effects, 96–97, 108
- exposure to, 6, 15
- fetal effects, 21–22, 96–97

- indoor air (*See* clean air policies)
- smoking prevention and, 635
- Surgeon General's Report (2006) on, 6, 15
- selection, peer pressure and, 520
- self-efficacy, 447–448, 509, 632
- self-help booklets for families, 552–553
- self-identity, 564, 632–633
- self-image, 509, 512, 633
- self-reported data, validity of, 215, 713
- self-service cigarette displays, 543
- sensation seeking
  - antismoking campaigns and, 690–691
  - movie smoking and, 592
- sensory transfer, 532
- serotonin pathway genes, 26, 452
- SES. *See* socioeconomic status
- SEU. *See* subjective expected utility
- sexual activity, 195, 375
- shape of packaging, 533–535
- siblings, smoking by, 444
- single nucleotide polymorphisms (SNPs), 452
- situational factors, 215
- size of packaging, 533–535
- Skoal (brand)
  - dissolvables, 507
  - market share, 164, 201–202, 273, 275, 277
  - product design, 540
  - Web site, 548
- “slim” descriptors, 31, 530–531
- “slim” packaging, 533
- small social groups. *See also* family; peer groups
  - influences of, 439–445, 458
  - smoking prevention in, 719–720
- “SMART (Skills Mastery and Resistance Training) Moves” program, 555
- Smee Report (UK), 513
- smoke
  - product design and, 535–539
  - secondhand (*See* secondhand smoke)
- Smoke-free Kids program, 721, 725–726
- SmokeLess States, 694, 696
- Smokeless Tobacco Master Settlement Agreement (1998), 507
- smokeless tobacco products
  - definition of, 6
  - digital marketing, 548–549
  - electronic cigarettes (e-cigarettes), 155, 549–551
  - flavor additives, 539
  - health warnings, 810
  - marketing expenditures, 491, 501–507
  - packaging, 531, 533, 540–541
  - pricing, 202, 706, 802
  - product design, 539–541, 600
  - taxes on, 698
  - tobacco control policies, 802
- smokeless tobacco use
  - academic achievement and, 161–162
  - age at onset, 201, 272, 291–293
  - brand preferences, 164, 201–202, 273–275, 277–278
  - cessation of, 804–808
  - current prevalence, 142, 144, 146, 164, 200–201, 269–271, 374, 382–388
  - etiology of, 430
  - ever used, 199–200, 267–268, 392
  - genetic factors, 454
  - health consequences, 199, 428, 806, 808
  - initiation of, product design for, 539–541
  - knowledge and attitudes about, 427–428
  - measures of, 216–217, 419–421
  - multiple tobacco product use, 154–155, 165, 207–209, 262, 287, 289–290, 404
  - prevention of, 801–804
  - substance use comorbidity, 193–194, 276, 371
  - trend data, 144–149, 195, 202, 293–294, 389–392
- The Smoker's Club (Web site), 550
- smokers' rights groups, 548–551
- smoking
  - cigars (*See* cigar smoking)
  - definition of, 6
  - health consequences of (*See* health consequences)
  - reasons for (*See* etiology of tobacco use)
  - statistics on (*See* epidemiology)
- smoking behavior
  - acquisition of (*See* initiation of smoking)
  - first use (*See* age at onset)
  - heritability of (*See* genetic factors)
  - movie depictions of (*See* movie smoking)
  - number per day (*See* intensity of smoking)
  - psychosocial factors (*See* etiology of tobacco use)
  - quitting (*See* smoking cessation)
  - trajectories of
    - developmental stages, 429–430
    - epidemiology, 180–181, 245–248, 344
    - risk factors, 428–429
  - transitions in, 181–183, 246, 248
- Smoking Beliefs and Attitudes Questionnaire, 44
- smoking cessation, 792–801
  - attempts at
    - definition of, 216, 419
    - epidemiology, 191, 262, 317–327, 368, 411–412
  - developmentally appropriate programs, 792
  - electronic technology, 800–801
  - intensity of smoking and, 184
  - lung function and, 83
  - pharmacologic adjuncts, 635, 800
  - pricing and, 705
  - program effectiveness, 792–800
  - summary, 801
  - weight gain after, 59, 69–70, 75–77
- Smoking Consequences Questionnaire (SCQ), 42–43, 447
- Smoking Lobby (Web site), 550
- smoking prevention
  - approaches to, 632–633, 731–732
  - clean air (*See* clean air policies)
  - clinic-based (*See* clinical interventions)
  - community interventions, 692–693, 811
  - youth empowerment and activism, 789–792

- conclusions, 10, 812
- developmental aspects, 632–633
- evaluation methods, 213, 558–561, 633–634, 636
- evidence summary, 809–811
- family-based (*See* family interventions)
- history of, 631
- mass media (*See* mass media antismoking campaigns)
- message strategy, 558, 686–688
- policies (*See* tobacco control policies)
- recommendations, 853–856
- school-based (*See* school-based programs)
- social environment and, 632–633, 719–720
- state-level programs, 694–697, 811, 849
- taxes (*See* taxation)
- theories underlying, 631–634, 809
- tobacco industry-sponsored (*See* tobacco industry)
- Smoking Situations Questionnaire (SSQ), 69
- SNPs. *See* single nucleotide polymorphisms
- snuff. *See* smokeless tobacco products
- snus
  - marketing of, 507, 549
  - packaging of, 533
  - prevalence of use, 155, 274, 278
  - product design, 540–541
- Social Cognitive Theory, 448, 599, 631, 636, 786, 806
- social-contextual stream, 509–511, 599, 632–634
- social ecological perspective, 428–429, 631
- social environment
  - large, 431–437, 458
  - marketing and, 509
  - protective factors in, 631
  - school (*See* school environment)
  - small groups, 439–445, 458 (*See also* family; peer groups)
  - smoking prevention and, 632–633, 719–720
- socialization, 520, 564
- social learning theory, 439, 447–448
- social networking Web sites, 549–551, 688
- social networks, 441–442
- social/normative stream, 632–634
- social trendsetters, young adults as, 522
- socioeconomic status (SES)
  - antismoking campaigns, 690
  - cigar smoking, 395
  - clean air policies, 707, 709
  - cultural influences, 433–434
  - current smoking prevalence, 175, 177, 233
  - health warnings and, 718–719
  - movie smoking, 569
  - point-of-sale marketing, 542–543
  - as risk factor, 427, 434
  - smokeless tobacco use, 200–202, 271, 388, 803
  - smoking trend data, 142, 189
  - tobacco use disparities, 153–154
  - youth access, 712
- sociometric status, 442
- Solutions for Smoking (SOS) training, 729
- South Carolina COPE program, 726
- South-East Asia (SEARO), tobacco use, 209–210
- age of onset/ever smoked, 303–304, 407–408
- current prevalence, 325–326, 334–335, 409–410
- intensity of smoking, 314–315
- smoking cessation, 325–326, 411–412
- Spain
  - marketing influences, 517
  - school-based programs, 786
  - “special edition” packaging, 533
  - specialty cigarettes (bidis & kreteks)
    - measures of use, 217, 423–424
    - prevalence of use, 206–207, 217, 288, 400–403
  - specialty item distribution, expenditures on
    - cigarettes, 490–493, 497–500
    - smokeless tobacco, 501, 503, 505–506
  - specificity of association, 7
- SPMs. *See* subsequent participating manufacturers
- sponsorships
  - bans on, 491, 534
  - expenditures on
    - cigarettes, 490–492, 494, 497–500
    - smokeless tobacco, 501–507
  - promotion of, 534
- sports participation, 437, 455
- smokeless tobacco use during, 803–808
- stage models, 181–182, 429–430
- standardized packaging, 532–533
- Stanford Five-City Project, 637
- State Cancer Legislative Database, 709
- state governments
  - clean air policies, 707–710
  - taxes, 699–700, 704 (*See also* taxation)
  - tobacco control programs, 694–697, 811, 849, 853
  - youth access laws, 710–712, 810
- Statewide Youth Movement Against Tobacco Use (SYMATU)
  - programs, 790
- statistical methods, 8, 134. *See also specific method or study*
- Steering Clear program, 726
- stereotypes of smokers, 509, 520
- Stoker’s chew (brand), 275
- Stomp Out Smokes program, 800
- streams of influence, 509–511, 632–634
- strength of association, 7
- stress, 445
- stroke, 199
- SSQ. *See* Smoking Situations Questionnaire
- Study of Smoking and Tobacco Use Among Young People, 702, 705, 709, 788
- subjective expected utility (SEU), 42–43
- subsequent participating manufacturers (SPMs), 525–526
- Substance Abuse and Mental Health Services Administration (SAMHSA), 190, 213, 854
- substance use. *See also specific drug*
  - nicotine addiction and, 184–185, 252–255
  - prevalence of, 194–195
  - psychiatric comorbidity, 27–28
  - tobacco use comorbidity, 193–194, 203, 205–206, 263–264, 276, 287, 371
  - tobacco use risk, 28–29

- suicidal ideation, 195–196, 376
- “Support the Law...It Works!” program, 555
- Surgeon General's Report (1964), 95, 431, 714, 849
- Surgeon General's Report (1979), 849–850
- Surgeon General's Report (1983), 95
- Surgeon General's Report (1988), 23, 69–70
- Surgeon General's Report (1989), 487
- Surgeon General's Report (1990), 69–70
- Surgeon General's Report (1994), 3–4, 849
  - advertising imagery, 574
  - continuum of smoking behavior, 181
  - developmental stages, 429, 509
  - epidemiology, 131, 134, 156, 164, 185, 189, 191
  - health consequences, 15–16, 79–80, 87, 95
  - psychosocial risk factors, 427–428, 519
  - smokeless tobacco use, 201, 208
  - smoking prevention programs, 631, 637, 683, 731
  - substance use, 193
  - taxation since, 698
  - tobacco industry marketing, 487
  - youth access, 710
- Surgeon General's Report (1998), 4, 188, 487
- Surgeon General's Report (2000), 4, 487, 511, 698, 849, 853
- Surgeon General's Report (2001), 4, 512
- Surgeon General's Report (2004), 4, 7
  - health consequences, 16–17, 20, 80, 87, 95, 108
- Surgeon General's Report (2006), 6, 17–21, 95
- Surgeon General's Report (2010), 4
  - genetic influences, 451
  - health consequences, 86, 95
  - nicotine addiction, 23, 26
- Surgeon General's Report (2012)
  - conclusions, 8–10 (*See also* conclusions)
  - evidence evaluation, 7–8
  - focus of, 6
  - organization of, 6–7
  - preparation of, 7
- surveillance systems, 131–133
- susceptibility to smoking
  - epidemiology, 179, 185, 243, 295–305
  - marketing influences, 512–513, 515, 520
  - stage models, 181–182, 429–430
- Sweden, health consequences, 94, 199
- Swedish council for Information on Alcohol and Other Drugs, 210
- Sweet Dreams (brand), 205
- Swisher Sweets (brand), 205, 282, 284–285
- SYMATU. *See* Statewide Youth Movement Against Tobacco Use
- Synar Amendment (*ADAMHA Reorganization Act*), 631, 710–712, 810, 854
- “Talk. They’ll Listen” campaign, 557, 561, 635
- TAPP. *See* Tobacco and Alcohol Prevention Project
- target rating points (TRPs), 689, 853
- Task Force on Community Preventive Services, 695, 734
- taxation, 697–707
  - avoidance of, 706
  - federal, 698–699
  - impact on tobacco use, 699–706
  - online tobacco sales, 547
  - pricing and, 523–524, 526–527, 699
  - state and local, 699–700, 704
  - summary, 706–707
- Teague, Claude E., Jr., 536
- Teenage Attitudes and Practices Survey, 43, 198
- Teitelbaum, Shari, 521
- telephone advertising, expenditures on, 491, 493–494, 502–503
- telephone-based cessation programs, 801, 807
- television advertising
  - ban on, 507, 635
  - econometric analyses of, 514
  - imagery in, 437–438
  - smoking prevention programs, 553, 557–563, 688
- television viewing, prevalence of, 196, 378
- Tempo (brand), 521
- temporal relationship of association, 7
- testimonials, expenditures on, 490, 501, 503
- Test Pilot* (movie), 565–566
- Texas, tobacco control program, 694, 853
- text messaging, smoking cessation using, 801
- Thailand
  - health warnings, 719
  - marketing practices, 534, 545
- Theory of Planned Behavior (TPB), 509, 599, 636
- Theory of Reasoned Action (TRA), 509, 636
- Theory of Triadic Influences (TTI), 428–429
  - impact of marketing, 509–510, 512, 516, 599
  - smoking prevention theories based on, 632–634, 809
- “thin” descriptors, 31, 530–531
- “Think. Don’t Smoke” campaign, 554, 557, 561, 635, 687
- thrombosis, 96
- Thumbs Up! Thumbs Down! (TUTD) Project, 569
- tie-ins, tobacco/movie industry, 565
- Timber Wolf, 274–275, 278
- time-series studies
  - marketing, 514, 713, 715
  - smoking prevention, 634
- Time Warner, 570
- TNT. *See* Project Towards No Tobacco Use
- To Have and Have Not* (movie), 565
- Tobacco: Helping Youth Say No* (brochure), 553
- Tobacco and Alcohol Prevention Project (TAPP), 785
- tobacco control policies
  - antismoking campaigns (*See* smoking prevention)
  - clean air (*See* clean air policies)
  - history of, 849–850
  - Internet campaigns against, 548–549
  - marketing practices and
    - movie smoking, 571, 598

## T

---

- TagSNPs, 452
- “Take 10” campaign, 557
- Taking Action to Reduce Tobacco Use* (IOM), 4

- packaging, 534–535
  - point-of-sale, 545
  - pricing, 527–528
  - product design, 541
  - recommendations, 853–856
  - since 1994 Surgeon General's Report, 3–4, 852
  - smokeless tobacco, 802
  - state-level, 694–697, 811, 849, 853
  - taxes (*See* taxation)
  - youth access programs, 555–557, 710–712, 810
  - tobacco industry. *See also specific company or brand*
    - attitudes toward, 554–555, 558–559, 635
    - conclusions, 10, 601–602
    - evidence summary, 598–601
    - marketing by (*See* marketing practices; *specific practice*)
    - position and behavior of, 517–522
    - retailers (*See* retail outlets)
    - smoking prevention programs, 552–564
      - community partnerships, 555
      - competition with marketing, 511
      - industry paradigm shift, 552–553
      - mass media, 557–563, 635, 687
      - sales to minors prevention, 555–557
      - school-based, 554–555
      - self-help booklets for families, 552–553
      - summary, 563–564, 601
    - summary, 487, 851
  - Tobacco Institute
    - Helping Youth Decide* booklet, 552–553
    - “It's the Law” program, 555–557
    - smoker's rights campaigns, 550
  - “Tobacco is Whacko if You're a Teen” campaign, 557, 561, 635
  - Tobacco Product Scientific Advisory Committee (TPSAC), 539
  - tobacco use
    - cigarettes (*See* smoking)
    - cigars (*See* cigar smoking)
    - definition of, 6
    - disparities in, 149–154
    - international statistics on (*See* worldwide tobacco use)
    - measures of, 215–217, 415–424
    - multiple product use, 154–155, 165, 205–209, 262, 276, 287, 289–290, 404–406
    - prevention of (*See* prevention programs; smoking prevention)
    - recent trends in, 850–852
    - risk factors for, 427–429 (*See also* etiology of tobacco use)
    - smokeless (*See* smokeless tobacco)
  - Tobacco Use Supplement to the Current Population Survey, 177, 435, 705, 707–708
  - tombstone advertising, 557
  - tooth decay, 199
  - TPB. *See* Theory of Planned Behavior
  - TPSAC. *See* Tobacco Product Scientific Advisory Committee
  - TRA. *See* Theory of Reasoned Action
  - Tracy, Spencer, 565–566
  - trademarks, on packaging, 530, 532–533
  - trajectories of smoking
    - developmental stages, 429–430
    - epidemiology, 180–181, 245–248, 344
    - risk factors, 428–429
  - transit advertising, expenditures on, 489, 491–493
  - transitions in smoking behavior, 181–183, 246
    - amount smoked (*See* intensity of smoking)
    - cessation (*See* smoking cessation)
    - effect of prices on, 703–706
    - initiation (*See* initiation of smoking)
  - Transtheoretical Model, 181
  - trend data
    - cigarette smoking, 138–143, 185–191, 257–260, 294, 345–363
    - cigar smoking, 149–151, 195, 205, 294, 399
    - smokeless tobacco use, 144–149, 195, 202, 293–294, 389–392
  - TRPs. *See* target rating points
  - “truth” campaign (American Legacy Foundation), 558, 561, 635, 687–690, 850
  - TTI. *See* Theory of Triadic Influences
  - TUTD. *See* Thumbs Up! Thumbs Down!
  - Turkey
    - academic achievement, 161
    - endothelial dysfunction, 108
  - twin studies
    - dyslipidemia, 108–109
    - genetic factors, 453–454
  - Twitter, 549
- ## U
- 
- ultimate factors, 509–511, 632
  - United Kingdom (UK)
    - health consequences, 88, 91, 102
    - marketing practices, 512–513, 517, 531–533
    - movie smoking, 569, 574
    - smoking prevention programs, 687, 692, 721, 786
    - weight control behavior, 32, 57, 63, 70
  - United States Junior Chamber, 555
  - United States regional variations
    - cigarette smoking
      - brand preferences, 177–178, 239–242
      - current prevalence, 175, 229–230, 339–343, 354–358
      - ever smoked, 174, 227–228
      - intensity of smoking, 176, 234–237
    - cigar smoking
      - brand preferences, 282–283, 285–286
      - current prevalence, 204–205, 280–281, 393–394, 396–398
      - ever used, 279
    - clean air policies, 708

smokeless tobacco use, 199–200, 267–268, 273–274, 382–386, 803  
brand preferences, 201–202, 277–278  
U.S. Census Bureau, 706  
U.S. Department of Agriculture (USDA), 199, 555  
U.S. Department of Education, 787  
U.S. Department of Health and Human Services (USDHHS)  
CDC (*See* Centers for Disease Control and Prevention)  
*Healthy People* objectives, 5, 135, 185, 711, 854  
strategic action plan, 854–856  
Substance Abuse and Mental Health Services Administration, 190, 213, 854  
U.S. Food and Drug Administration  
authority of, 4, 207, 545, 547, 810, 849, 852–854  
ban on flavorings, 164, 178, 205, 207, 539  
health warnings, 719, 810  
online sales/marketing regulations, 547–548  
“1996 rule” (advertising restrictions), 491  
tobacco advertising rules, 437, 557  
Tobacco Product Scientific Advisory Committee, 178  
U.S. Postal Service (USPS), 548  
U.S. Preventive Services Task Force (USPSTF), 727  
U.S. Smokeless Tobacco, 531, 548. *See also* Copenhagen; Skoal  
*United States v. Philip Morris*, 851  
Universal, 570  
UPS, 548  
Uptown (brand), 537  
“Upward Bound” program, 555

## V

validity  
advertising impact studies, 438, 514, 713–714  
tobacco use measures, 215  
vascular injury, 95–96  
vascular reactivity, 102, 108  
Vector Tobacco Inc., 488  
vending machines, 437, 710  
ventilated filters, 531, 536–537  
ventral tegmental area (VTA), 455  
video games, advertising in, 437–438, 546  
violence, 195–196, 376–377  
viral marketing, 552  
Virginia Slims (brand), 31  
Vital Statistics Natalality, 702  
Vlagtwedde/Vlaardingen study (Netherlands), 83  
VTA. *See* Ventral tegmental area

## W

Walgreens, 545  
“wallet packs,” 534–535  
Washington State Institute for Public Policy, 791  
water pipes (hookahs), 155, 206–207, 430

WCSS. *See* Weight Control Smoking Scale  
Web sites. *See also* digital marketing; *specific site*  
antismoking, 688  
cessation programs, 800–801, 807–808  
online tobacco sales, 547–548  
prosmoking, 548–551  
social networking, 549–551, 688  
tobacco company, 548–549  
expenditures on, 490, 493–494, 502–503, 546  
WE CARD Coalition, 556  
“We Card” program, 556–557  
Wegmans, 545  
weight control, 30–79  
advertising emphasizing, 31, 530–532  
beliefs about, 32–45  
evidence review methods, 30  
smoking behavior related to  
clinical studies, 60–63  
effectiveness of (*See* body weight)  
initiation of smoking, 63–68, 75–79  
population surveys, 45–60  
summary, 79  
Weight Control Smoking Scale (WCSS), 57, 60  
Western Pacific (WPRO), tobacco use, 209–210  
age of onset/ever smoked, 304–305, 407–408  
current prevalence, 326–327, 335–336, 409–410  
intensity of smoking, 315–316  
smoking cessation, 326–327, 411–412  
wheeze, 87–94  
cross-sectional studies, 88–91  
prospective cohort studies, 91–94  
summary, 94  
White Owl (brand), 205, 282, 284–285  
WHO. *See* World Health Organization  
whole-genome sequencing, 453  
Wilkerson Sword Company, 539  
Winston (brand), 535–536  
withdrawal symptoms, 23–24, 456  
World Health Organization (WHO)  
atherosclerosis study, 100  
Framework Convention on Tobacco Control (FCTC), 531, 545, 719  
Global Tobacco Surveillance System (GTSS), 156, 209–210  
movie rating recommendations, 571, 598  
*Report on the Global Tobacco Epidemic* (2011), 854  
smoking prevention campaign study, 563  
World Heart Federation, 100  
worldwide tobacco use, 156–157, 165, 209–210. *See also specific region or country*  
age of onset/ever smoked, 295–305, 407–408  
current prevalence, 317–336, 409–410  
intensity of smoking, 306–316  
international surveillance systems, 131–133  
other forms of tobacco than cigarettes, 413–414  
regulatory actions, 854  
smoking cessation, 319–322, 411–412  
WPRO. *See* Western Pacific

## Y

- 
- Yahoo!, 550  
 young adults  
   cigarette smoking  
     brand preferences, 161–164, 177–178, 190, 241–242, 507, 516  
     current prevalence, 137–139, 164, 174–175, 177, 232, 339–344, 364  
     developmental patterns, 179–185, 245–248, 344  
     disparities, 149, 152–154  
     initiation of smoking, 142–143, 179–180, 261  
     intensity of smoking, 249–251  
     nicotine addiction, 184–185, 254–256  
     trend data, 141–143, 177, 185–191, 258–260, 294, 359–363  
   cigar smoking  
     brand preferences, 164  
     current prevalence, 142, 146, 280–281, 393–398  
     trend data, 149, 151, 294  
   current trends, 850  
   definition of, 6  
   developmental risk factors, 428  
   educational level, 435  
   marketing aimed at, 508, 518–522  
   peer group influences, 440  
   price sensitivity of, 527–528, 704–705  
   smokeless tobacco use  
     brand preferences, 164, 277–278  
     current prevalence, 142, 146, 201–202, 269–270, 382–388  
     trend data, 144–149, 202, 292–294  
   water pipes (hookahs), 206  
   weight control  
     beliefs about, 32–45  
     smoking behavior, 45–60  
   young people, definition of, 6  
   youth access  
     industry-sponsored prevention programs, 555–557  
     physical environment, 437–438 (*See also* retail outlets)  
     regulations on, 710–712, 810  
   youth empowerment and activism, 789–792  
 Youth Risk Behavior Surveillance System (YRBSS)  
   overview and methods, 131, 214  
   smoking trend data, 138–142  
   tobacco use measures, 216–217, 415–424  
   weight control behavior, 58, 157  
 Youth Risk Behavior Survey (YRBS)  
   overview and methods, 131–133, 214  
   cigarette smoking  
     age at onset, 22, 180, 244  
     current prevalence, 135, 137, 164, 174–175, 187–189, 229–230  
     ever smoked, 173–174, 185–186, 227–228  
     initiation of smoking, 180  
     intensity of smoking, 175–177, 234–235, 237  
     prices, 702–703  
     projected rates, 854, 856  
     trend data, 138–142, 185–191, 347–349, 352–358  
   cigar smoking, 145, 149–150, 203–205, 280–281, 399  
   clean air policies, 709  
   health-related behaviors, 194–197, 372–381  
   multiple tobacco product use, 155, 207–209, 289–290, 404–406  
   smokeless tobacco use, 144–145, 147, 154, 164, 200–202, 269–270, 389–390  
   tobacco use disparities, 149, 154  
   weight control behavior, 157, 160, 197  
 Youth Smoking and the Media study (NCI), 558  
 YouTube, 688  
 YRBS. *See* Youth Risk Behavior Survey  
 YRBSS. *See* Youth Risk Behavior Surveillance System

